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A. Abbreviations 
Abbreviations are also defined where they first appear in the text. For 
amino acids the three letter code are used. 
 
4-IPP 4-iodo-6-phenylpyrimidine 
Å Ångstrom (1 Å = 10-10 m) 
ARDS Acute respiratory distress syndrome  
CD74 Major histocompatibility complex, class II invariant 
chain 
CL Cutaneous leishmaniasis 
D-dopachrome 2-carboxy-2,3-dihydroindole-5,6-quinone 
DMEM Dulbecco’s modified Eagles’s medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
E. coli Escherichia coli 
ELISA Enzyme-linked immunosorbant assay 
ERK Extracellular signal-regulated kinases 
FBS Fetal bovine serum 
HPP Hydroxyphenylpyruvate 
IFN Interferon 
IL Interleukin 
iNOS Inducible nitric oxide synthase 
IPTG   Isopropyl β-D-thiogalactopyranoside 
ISO-1 (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole 
acetic acid methyl ester 
Jab1 Jun activation domain binding protein 1 
Kd Dissociation constant 
kDa kilo-Dalton (1 kDa = 1.6605 ◦ 10-21 g) 
LmMIF MIF ortholog from L. major 
LPS Lipopolysaccharide 
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MAD Multiple Anomalous Dispersion 
MAPK Mitogen activated protein kinase 
MIF Macrophage migration inhibitory factor 
NAPQI N-(4-oxo-1-cyclohexa-2,5-dienylidene)acetamide 
NK cells Natural killer cells 
NMR Nuclear Magnetic Resonance 
NO Nitric oxide 
OD Optical density 
OXIM-11 (E)-4-hydroxybenzaldehyde O-cyclohexanecarbonyl-
oxime 
PAGE Polyacrylamide gel electrophoresis 
PBMC Peripheral blood mononuclear cells 
PbMIF MIF ortholog from P. berghei 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PDB Protein Data Bank 
PEG   Polyethylene glycol 
PfMIF MIF ortholog from P. falciparum 
PGE2 Prostaglandin E2 
PMN Polymorphonuclear neutrophil granulocytes 
PMSF Phenylmethyl-sulfonylfluoride 
RMSD Root mean square deviation 
SDS Sodium dodecyl sulfate 
Th cells T-helper cell 
TLR Toll like receptor 
TNF Tumor necrosis factor 
Tris 2-amino-2-hydroxymethylpropane-1,3-diol 
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1 Introduction 
1.1 Parasites and Disease 
Millions of people world-wide are affected by diseases caused by parasites. 
In developing and tropical regions, parasites represent a major cause of 
death, making parasitic infections one of the world’s most important 
health problems.    
Parasitic protozoa are unicellular eukaryotic pathogens that live inside 
host cells and/or in extracellular fluids. They are responsible for diseases 
such as malaria, trypanosomiasis, schistosomiasis and leishmaniasis. The 
parasites initiate a relationship with their host to increase their own 
chances of survival, proliferation and propagation. An optimal relationship 
for parasites to their hosts consists of a high prevalence with minimal 
symptoms of disease to guarantee a lifelong persistence and ample time 
for the passage to new hosts. However, the vertebrate’s immune system 
mobilizes its immunological arsenal to eliminate the infectious agents. In 
response, parasites have evolved highly specialized strategies to evade 
immune destruction and to complete their life cycle (1).   
Several host and parasite-specific factors play a role in the persistence of 
parasites within infected cells and in influencing the clinical manifesta-
tions of the disease. Recent observations indicate that parasitic pathogens 
ensure their survival by a production of immunomodulatory proteins 
which interact with specific molecular pathways in the host to alter 
normal protein functions and manipulate the ensuing immune response 
(2). 
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1.1.1 Mechanisms of Immune Evasion 
There are abundant examples of parasites escaping the effects of adaptive 
humoral and cellular immunity by producing immunomodulatory proteins. 
Well documented examples of such immune evasion strategies include 
filarial nematodes which express the protease inhibitor CPI-2 to inhibit 
Class II antigen presentation, thereby preventing development of active 
immunity (3). Another strategy to evade the host immune response is the 
antigenic variation used by protozoa such as African trypanosomes and 
malaria parasites. Surface molecules that are important targets of the 
humoral immune response are encoded in the genome as multicopy, 
nonallelic gene families that show little or no immunological cross-
reactivity. The successive expression of members of these gene families 
outmaneuvers the host’s humoral response (4, 5). One of the most 
sophisticated mechanisms of immune evasion strategies, the selective 
activation of specific subsets of T helper cells, is described for Leishmania 
major. It was recently demonstrated that L. major actively induces 
interleukin 10 (IL-10)-producing CD25+ regulatory T cells to prevent 
complete clearance of the parasite (6). IL-10 has been described 
extensively as a key immunoregulator during infection as a suppressive or 
deactivating cytokine (7-10). It has been shown to suppress cytokine 
production of both T and natural killer (NK) cells and intracellular killing 
of pathogens. Furthermore, IL-10 inhibits a broad spectrum of activated 
macrophage/monocyte functions, including NO production, expression of 
class II MHC, and molecules such as IL-12 and CD80/CD86.  
The remarkable diversity of vertebrate immune evasion mechanisms has 
been reviewed recently by Paul Schmid-Hempel (11), an overview of the 
manifold immune evasion strategies is given in Figure 1. 
Introduction 
8 
 
 
Figure 1. Interference of parasites with the vertebrate immune system. 
Extending over hours, days and years post-infection, different types of immune evasion 
strategies are employed. Defense mechanisms of the host are indicated below the arrow 
and the corresponding interference of the parasites are indicated above the arrow. Figure 
taken from (11). 
 
 
 
1.2 Leishmaniasis 
The parasites responsible for the disease leishmaniasis are among the 
most diverse of human pathogens, both in terms of their geographical 
distribution and variety of clinical syndromes they produce (12). 
Leishmania, a protozoa of the family Trypanosomatidae, currently affects 
12 million people in 88 countries (Figure 2A). There are an estimated 2 
million new infections and 70000 deaths each year (13). It is estimated 
that over 350 million people are living in regions with a risk of infection 
(13).  
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Figure 2. Geographical distribution and clinical signs of leishmaniasis. (A) 
Geographical distribution  (B) A patient from Uganda with visceral leishmaniasis (C) A 
patient from Peru with cutaneous leishmaniasis. (D) A patient from Bolivia with mucosal 
leishmaniasis. Figure A is taken from (14), figures B-D are from (15).   
 
 
The clinical manifestations caused by Leishmania species are divided into 
two major categories: cutaneous and visceral leishmaniasis (Figure 2B-D). 
Cutaneous leishmaniasis (CL), the most common form can further be 
subdivided into localized CL, diffuse CL and mucocutaneous CL. The first 
sign of infection is typically a small sore where the infected sandfly has 
bitten the host that develops progressively over a period of 2 to 6 weeks to 
the typical ulcer that characterizes localized CL (16). This form of 
cutaneous leishmaniasis can spread from the initial site of infection and 
develop to diffuse CL, covering the patient’s entire body. Mucosal 
leishmaniasis is the most serious complication and can lead to disfiguring 
and life-threatening leishmaniasis. It can develop at the same time with 
localized CL or even 1 – 5  years after the localized ulcer has healed.   
While skin sores of cutaneous leishmaniasis will often heal on their own, 
leaving unpleasant looking scars, visceral leishmaniasis can cause death if 
not treated. The variety of clinical syndromes is caused due to the variety 
of Leishmania species and subspecies with more than 20 infect humans, 
each causing a different spectrum of symptoms (17). 
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1.2.1 Leishmania Life Cycle 
Leishmania is spread through sandflies belonging to the genus 
Phlebotomus in Europe, Africa, Middle East and Asia and through the 
genus Lutzomyia in America (18).  
When taking a blood meal, the infected female sandfly injects 
Leishmania promastigotes into the skin. Within the human host, the 
promastigotes then are ingested rapidly by phagocytes. The first 
phagocytic cells that infiltrate the site of experimental infection with L. 
major promastigotes are polymorphonuclear neutrophil granulocytes 
(PMN), followed by a wave of macrophages (19). PMNs phagocytose the 
parasite but do not kill it; instead they serve as intermediate host cells. 
The Leishmania promastigotes delay the spontaneous apoptosis of the 
infected PMNs for up to three days and remain inside the PMN without 
multiplication or transformation (20, 21). After 3 days, the much longer 
living macrophages arrive at the site of infection and phagocytose the 
apoptotic PMN infected with the parasite. Here, the promastigotes 
metamorphose into amastigotes and replicate until the host cell 
eventually bursts. Released amastigotes then infect other phagocytic cells 
and continue the cycle. When blood-feeding on an infected host, naïve 
sandflies become infected with amastigotes. In the stomach of the insect, 
the amastigotes transform almost immediately into the promastigote form 
and the cycle continues (Figure 3).   
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Figure 3. The Leishmania Lifecycle. Leishmaniasis is transmitted through the bite of 
a female sandfly. During their blood meal, infected sandflies inject the infective stage, the 
so-called promastigote parasite, into the human host [1]. Injected promastigotes are 
phagocytized by macrophages [2] and transform into the amastigote parasites [3]. These 
multiply in the infected cells and also affect different tissues, depending on the 
Leishmania species [4], which causes the corresponding clinical manifestation of the 
disease. When sandflies take blood meals from an infected host, they take up parasitized 
macrophages [5, 6]. In the vector fly's midgut, these parasites differentiate into the 
promastigote form [7], which multiplies and finally migrates to the fly's proboscis [8]. 
Figure is taken from (14). 
 
 
1.2.2 Host Defense and Parasite Interactions 
Leishmania parasites live exclusively in mononuclear phagocytes, but lack 
any mechanism to penetrate the membranes of their host cells. After 
infection, most Leishmania promastigotes are rapidly killed in the 
extracellular tissue environment; their survival depends on the rapid 
escape from the toxic extracellular milieu via the ingestion by phagocytes. 
Following infection, a local inflammatory response is initiated leading to 
an accumulation of leukocytes at the site of parasite delivery (22). The 
composition of the cells defining this early accumulation appears to be the 
determinant of the later outcome of the disease as the further steps of 
immune defense are decided by the specific subset of cytokines released. 
The balance of these inflammatory responses mediates disease expression 
Introduction 
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and may result in either symptomless infection, self healing local CL 
leading to immunity, or chronic leishmaniasis.    
While infected macrophages preferentially produce interleukin (IL)-1β, IL-
12 and tumor necrosis factor α (TNF-α), T-helper cell type (Th)-1 cells 
produce predominantly interferon (IFN)-γ, Th-2 cells produce IL-4, 
dentritic cells produce IL-12 and natural killer cells produce IFN-γ (23).  
Of particular importance for the disease development is whether the 
released set of cytokines leads to a Th1-dominated immune response, 
accompanied by cell-mediated immunity (macrophage activation), or to a 
Th2-dominated immune response which regulates an antibody response.  
The control and clearance of Leishmania is mainly mediated by the Th1-
type immune response. Experimental studies in murine models have 
established a clear difference between Th2-mediated disease susceptibility 
and Th1-mediated protection (24). Th1-cells produce IFN-γ, which 
subsequently induces the production of nitric oxide (NO) in phagocytic 
cells that harbor L. major  leading to destruction of the parasite (24-27).  
The parasites however actively induce the early secretion of IL-4, thus 
creating a microenvironment propitious for the development of Th2 cells 
(28). Further immunomodulating mechanisms include the Leishmania-
induced inhibition of chemotaxis by neutrophils and monocytes (29). In 
contrast, a more recent study found a chemotactic factor released from the 
Leishmania parasite in the early phase of infection. This factor has a size 
between 10 and 50 kDa and was suggested to be responsible for the 
accumulation of neutrophilic granulocytes following infection (30). The 
parasite also stimulates the production and release of PGE2 (31) and 
promotes its survival inside the macrophage by preventing apoptosis (32). 
As described later in section 1.5, these mechanisms also are known 
functions of the cytokine macrophage migration inhibitory factor (MIF).  
Additional immune evasion mechanisms proposed for Leishmania are 
listed in Table 1. 
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Table 1. Immune evasion mechanisms of Leishmania spp. Adapted from 
(Zambrano-Villa et al., 2002). 
 
Main strategies of evasion Result 
Inhibition of phagolysosome forma-
tion and the proteolytic enzymes 
from lysosomes 
Evades the macrophage proteolytic 
process 
Activation of protein kinase C and   
scavenging of oxygen intermediates  
Inhibits respiratory burst 
 
Prevention of apoptosis of infected  
macrophages 
Extends the survival of the infected 
macrophage 
Inhibition of MHC-protein produc-
tion, peptide loading and expression 
of co-stimulatory molecules 
Impairs macrophage antigen- 
presenting function 
Induction of PGE2 and downregu-
lation of TNF-αR  
Impairs macrophage function 
 
Inhibition of macrophage and neu-
trophil chemotaxis 
Promotes survival of parasites once 
established 
Shedding of MAC complex and in-
activation of some MAC components 
Resists complement 
 
Suppression of transcription of the 
IL-12 gene and induction of IL-10 
Blocks the protective Th1 response 
Abbreviations: IL-10, interleukin 10; IL-12, interleukin 12; MAC, membrane attack 
complex; MHC, major histocompatibility complex; PGE2, prostaglandin E2; TNF-αR, 
tumor necrosis factor α receptor. 
 
 
 
1.2.3 Treatment 
Cutaneous leishmaniasis is non-fatal and often self-healing; therefore 
therapy is not routinely indicated for uncomplicated localized CL. 
However, non-healing, severe and disfiguring lesions are treated to 
accelerate cure, to reduce scarring and to prevent parasite dissemination. 
One of the main problems in treating CL is the difficult clinical diagnosis 
of the broad clinical spectra. The available drugs to treat leishmaniasis 
can have serious side effects and because of drug-resistant parasites 
strains (33) and immunosupression in cases of HIV infection, reports of 
patients non-responsive on drugs are increasing (34).  
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1.3 Malaria 
Malaria is an intracellular infectious disease caused by a protozoan 
parasite of the genus Plasmodium. The single-celled eukaryotes are 
transmitted by the female Anopheles mosquitoes during their blood meal. 
Four types of the Plasmodium parasite can infect humans: Plasmodium 
falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium 
malariae. P. falciparum is the main cause of severe clinical malaria and 
death. Approximately 3.2 billion people live in areas at risk of malaria, 
and in the year 2002, it was estimated that Plasmodium falciparum alone 
caused 300 – 660 million episodes of clinical malaria infections (35), killing 
approximately 1 – 2 million people, mostly children under the age of 5. 
(WHO, The Impact of Malaria, a Leading Cause of Death Worldwide). 
Most clinical events attributable to P. falciparum are  concentrated in the 
African region (70%), but the highly populated South East Asia region 
contributes 25% of the world's clinical attacks in 2002 (35) (Figure 4). 
People with malaria typically have cycles of chills, fever, and sweating 
that re-occur every 1 – 3 days. Nausea, vomiting, and diarrhea often go 
along with the fever and the destruction of red blood cells causes anemia. 
When the patients survive, recovery is usually complete, but it can also 
leave some patients with long-term neurological deficits. 
 
 
Figure 4. P. falciparum endemic distribution. Endemicity classes: light green, 
hypoendemic (areas in which childhood infection prevalence is less than 10%); medium 
green, mesoendemic (areas with infection prevalence between 11% and 50%); dark green, 
hyperendemic and holoendemic (areas with an infection prevalence of 50% or more). 
Unclassified areas (yellow). Grey areas are a combined mask of areas outside of the 
transmission limits and areas of population density less than 1 person km-2 .Figure and 
text are from (35). 
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1.3.1 Plasmodium spp. Life Cycle 
The life cycle of Plasmodium spp. is complex and is divided into several 
stages. Here, a simplified outline: 
Sporozoites injected from the female Anopheles mosquito migrate within 
the human bloodstream to the liver and infect hepatocytes. During the 
next 9 – 16 days, the liver-stage parasites differentiate and undergo 
asexual multiplication resulting in tens of thousands of merozoites which 
eventually burst from the hepatocyte. The merozoites then enter the 
bloodstream and each potentially invades an erythrocyte, where they 
undergo another round of multiplication within 48 hours, producing 12 – 
16 merozoites within a schizont. The synchronized rupture of the red blood 
cells full of merozoites induces the typical bouts of fever and chills in the 
infected individual. The released merozoites invade additional red blood 
cells and carry on the cycle, progressively breaking down the red cells. 
Merozoites may also differentiate into gametocytes which do not rupture 
the erythrocyte. These sexual forms are taken from the bloodstream by a 
feeding Anopheles spp. mosquito and fertilize in the mosquito midgut to 
form zygotes. The parasites multiply in the mosquito where they develop 
into sporozoites (36, 37). 
 
Figure 5. The malaria parasite life 
cycle. During a blood meal, a 
malaria-infected female Anopheles 
mosquito inoculates sporozoites into 
the human host. Sporozoites infect 
liver cells and mature into schizonts, 
which rupture and release merozoites. 
After the initial replication in the 
liver the parasites undergo asexual 
multiplication in the erythrocytes. 
Merozoites infect red blood cells). The 
ring stage trophozoites mature into 
schizonts, which rupture releasing 
merozoites. Some parasites 
differentiate into sexual erythrocytic 
stages (gametocytes) and are ingested 
by an Anopheles mosquito during a 
blood meal. The parasites multiply in 
the mosquito where they develop into 
sporozoites (image taken from 
www.learner.org). 
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1.3.2 Host Defense and Parasite Interaction 
During most of its human life cycle the malaria parasite resides within 
liver and blood cells, and therefore is relatively invisible to the host’s 
immune system. However, mature parasitized red blood cells are cleared 
by the spleen. To avoid this destruction, maturing parasites in red blood 
cells express receptor-adhesive proteins on the surface of infected cells 
mediating adhesion in the vascular beds of organs, a process known as 
sequestration (38). However, the most notorious survival mechanism of 
the parasite is its ability to undergo almost unlimited antigenic variation 
by changing its antigens on the infected erythrocyte surface (39). 
The importance of cytokines and their contribution in severe malaria have 
been studied (37). Malaria parasites modify the production of several 
cytokines. Protection against malaria may be mediated by TNF-α and 
IFN-γ and the release of mediators such as NO. Malaria pathogenesis has 
further been associated with ICAM-1, VCAM-1, E-selectin, MIF, iNOS and 
uPAR. Further modifications of the immune response induced by P. 
falciparum are a decreased number of circulating T lymphocytes and a 
marked increase in apoptotic human mononuclear cells (40). An overview 
of immune evasion mechanisms of P. falciparum is shown in Table 2. 
 
Table 2. Immune evasion mechanisms of P. falciparum. Adapted from Zambrano-
Villa et al., 2002. 
 
Main strategies of evasion Result 
Antigenic variation and/or 
polymorphisms 
Evades the IR; infected cells are 
prevented from being swept to the 
spleen 
Induction of blocking antibodies Blocks the binding of real inhibitory  
antibodies 
Molecular mimicry Alters immune recognition and might 
induce autoimmune disease 
Anergy of T cells Immunosuppression 
Altered peptide ligand Alters functions of memory T cells 
Abbreviations: IR, immune response 
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1.4 Macrophage Migration Inhibitory Factor (MIF) 
1.4.1 MIF is a Proinflammatory Cytokine 
Cytokines are a family of water-soluble signaling proteins with a mass of 8 
to 30 kDa that function primarily to effect communication between 
different cell types. They are important regulators of the innate and 
adaptive immune response and are often secreted by cells of the immune 
system in response to pathogens. Released by one activated cell they act 
through a receptor on their target cell to activate and recruit more 
immune cells as a way to counter the infectious agent.  
Macrophage migration inhibitory factor (MIF) was first described in 
the late 1950s as a product of activated lymphocytes that inhibits the 
random movement of cultured macrophages (41, 42). In the following 
years, MIF production was shown to correlate with general macrophage 
functions such as adherence and phagocytosis (43-45). The breakthrough 
for understanding the molecular mechanisms however began only in 1989, 
when the MIF cDNA was isolated and cloned for the first time (46). 
Since then, the knowledge about MIF’s role as an important regulator of 
inflammation and autoimmunity has increased rapidly. In 1993, MIF was 
identified to be released from pituary cells after stimulation with 
endotoxins and to potentiate endotoxemia (47). One year later, 
macrophages were described as an important source of MIF and to release 
the cytokine after stimulation with proinflammatory stimuli such as 
bacterial lipopolysaccharide (LPS), TNF-α or IFNγ (48). With the 
expression and purification of recombinant MIF reported in the same year 
(49), MIF became available in large quantities to be investigated 
extensively. Together with genetic knockout studies in mice (50), the 
availability of recombinant MIF strongly aided in the discovery of MIF’s 
prominent position within the cytokine cascade upstream of TNFα, IL-1β, 
IL-2, IL-6, IL-8, IL-12 and IFNγ (51) .  
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In recent years, MIF has emerged as an important regulator of several 
autoimmune and inflammatory diseases, including septic shock, 
atherosclerosis, glomerulonephritis, arthritis and cancer (52). MIF-like 
proteins also have been reported recently in several parasitic species, 
including L. major with rising evidence that these orthologs play a role in 
immune evasion of the parasite (53). Consequently, structure-based design 
of small molecule antagonists targeting MIF is emerging for therapeutic 
purposes (54). 
 
1.4.2 MIF Receptors 
Although MIF was described as one of the first cytokines, the identity of 
MIF’s binding receptors CD74 and CXCR2/4 were not found until very 
recently (55, 56). 
 
1.4.2.1 CD74 Mediates ERK1/2 Activation  
Extracellular signal-regulated kinases (ERKs) act in a signaling cascade 
that regulates various cellular processes such as proliferation, differentia-
tion, and cell cycle progression in response to a variety of extracellular 
signals. 
CD74, a 31 – 41 kDa Type II transmembrane protein is also known as the 
cell surface form of the Class II-associated invariant chain (li). It has a 
short N-terminal cytoplasmic tail of 28 amino acids, followed by a single 
24-amino acid transmembrane region and, an approximately 150 amino 
acid lumenal domain (57). It was shown that MIF binds the extracellular 
domain of CD74 with high affinity (Kd = 9 × 10−9 M) and is required for the 
MIF-induced secretion of IL-8 (58) and the activation of the ERK1/2- and 
AKT signaling cascade, the production of prostaglandin E2 (PGE2) and cell 
proliferation (55) in a CD44-dependent manner (59, 60). The MIF-induced 
activation of ERK1/2 kinases is sustained for a period of at least 24 hours 
and is dependent upon protein kinase A activity (61). 
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1.4.2.2 CXCR 2/4 Mediates Cell Migration 
MIF acts as a major regulator of inflammatory cell recruitment and 
atherogenesis. In a recent study these chemokine-like functions of MIF 
were shown to be mediated through interaction to the chemokine receptors 
CXCR4 and CXCR2 (56). This study revealed that surface-bound MIF 
induces arrest of primary human monocytes through CXCR2 and of 
primary human effector T-cells through CXCR4. Furthermore, CD74 was 
implicated in CXCR2-mediated MIF-induced arrest. 
To test whether MIF directly triggers leukocyte chemotaxis through these 
receptors, Bernhagen et al. compared the promigratory effects of MIF on 
human blood mononuclear cell-derived monocytes expressing CXCR2 and 
on CD3+ T lymphocytes expressing CXCR4. MIF induced chemotaxis in 
both cell types, and, in monocytes, both CXCR2 and CD74 contributed to 
MIF-triggered chemotaxis.  
To assess the physical interactions of MIF with CXCR2 and CXCR4, 
receptor-binding competition and internalization studies were performed. 
MIF strongly competed with the cognate CXCR4 and CXCR2 ligands 
CXCL12 and CXCL8 for receptor binding with nanomolar affinity and 
elicited internalization of both receptors. The affinity of MIF for CXCR2 
(Kd = 1.4 x 10-9 M) and CXCR4 (Kd = 19.8 x 10-9 M) was comparable to the 
affinities of the cognate ligands CXCL8 and CXCL12, respectively. 
 
1.4.3 Apoptosis and Cell Proliferation 
Mitchell et al. showed that both endogenously secreted MIF and 
exogenously added recombinant MIF stimulate the proliferation of 
quiescent fibroblasts. This response is associated with the sustained phos-
phorylation and activation of the classical mitogen activated protein 
kinases (MAPK), ERK1/2. Activation of ERK leads to the phosphorylation 
and activation of the cytoplasmic phospholipase A2 (cPLA2) which then 
induces the release of the proinflammatory and growth-regulating factor 
Introduction 
20 
 
arachidonic acid. Correspondingly, the addition of a neutralizing 
monoclonal anti-MIF antibody inhibited the proliferative effect (61). 
AKT activation promotes a number of cellular responses that are 
associated with cell division, suppression of apoptosis, inactivation of cell 
cycle inhibitors, and induction of cyclin and cytokine gene expression (62). 
The AKT signaling cascade recently was reported to be activated by MIF 
in a CD74- and CD44-dependent manner with Src and PI3K as upstream 
signaling components (60, 63, 64). These studies describe that MIF 
augments NF- B function and increases expression of Bcl-XL and Bcl-2, 
leading to a suppression of apoptosis in several cell types including 
primary MEFs, fibroblast cell lines and B cells.  
In functional screens to isolate genes which bypass p53-mediated growth 
arrest or apoptosis, MIF was also identified as a negative regulator of p53 
activity. Treatment with MIF suppressed p53-dependent transcriptional 
activity and extended the live span of primary murine fibroblasts and 
macrophages (65). 
 
1.4.4 Glucocorticoids 
Glucocorticoids suppress cell-mediated immunity by inhibiting genes that 
encode for cytokines. Unlike other cytokines, secretion of MIF is induced 
rather than inhibited by low concentrations of glucocorticoids. Secreted 
MIF then was found to override glucocorticoid-induced inhibition of TNF, 
IL-1, IL6 and IL-8 secretion in LPS-stimulated human monocytes. In a 
mouse model of endotoxemia, MIF also was demonstrated to override the 
protective effect of glucocorticoids on LPS-induced lethality (66). Further 
studies showed that MIF counteracts the glucocorticoid induced suppres-
sion of arachidonic acid release (61), inhibition of T-cell proliferation, and 
IL-2 and IFNγ production (67). 
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1.4.5 MIF in Disease 
MIF has emerged to be an important regulator of several chronic and 
acute inflammatory diseases including septic shock (68), acute respiratory 
distress syndrome (ARDS) (69), rheumatoid arthritis (70), arteriosclerosis 
(71), glomerulonephritis (72), and cancer (73). MIF is released during the 
immune response by macrophages, activated T-cells and a variety of non-
immune cells. 
Analysis of the role of MIF during sepsis showed that the administration 
of recombinant MIF to mice greatly potentiates the effect of LPS alone, 
leading to decreased survival after challenge. When mice were injected 
with neutralizing anti-MIF antibodies prior to LPS administration, 
reduced proinflammatory cytokine production (TNF-α) and a significant 
reduction in lethality was observed (47). Similarly, mif-/- mice have 
diminished TNF-α levels and resistance to the lethal effects of high doses 
of the bacterial lipopolysaccharide, or Staphylococcus aureus enterotoxin B 
(50).  
MIF also plays a crucial pathological role in the acute respiratory distress 
syndrome (ARDS), which is a life-threatening disease characterized by 
diffuse inflammation of lung parenchyma. The common pathogenic event 
is neutrophilic inflammation of the airspaces, resulting in increased per-
meability of the alveolar capillary membrane, and destruction of the 
alveolar airspaces in the lungs. In patients, it was shown that MIF levels 
are upregulated in the alveolar airspaces (69). As assessed by anti-MIF 
antibody treatment in a mouse model, the elevated concentration of MIF 
leads to a increased activity and number of neutrophil granulocytes at the 
site of inflammation and alveolar inflammation (74).  
Recent studies also indicate a role for MIF in atherogenesis. Atherogenesis 
is characterized by a chronic inflammatory response in the walls of 
arteries with a continuous immigration and infiltration of activated 
macrophages and T-cells. The upregulation of MIF during progression of 
human atherosclerosis was first reported in 2002 (71). Importantly, MIF 
also is linked to atherosclerosis lesion development (75), and studies 
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involving mif gene-deficient mice or anti-MIF antibodies showed signifi-
cant reductions in atheroma lesions and in the inflammatory response 
associated with atherosclerosis development (75, 76). 
Numerous reports have linked MIF to cancer. In general, MIF has been 
described to be highly overexpressed in cancer cells and it has been 
proposed as a bio-marker of prostate cancer (77) and colorectal carcinoma 
(78). High levels of MIF also have been observed in the pituitary (79), skin 
(80), breast (81), brain (82) liver (83) and ovarian (84) tumors. Despite the 
abundant evidence for the link between MIF and cancer, the molecular 
mechanisms by which MIF mediates tumorgenesis are largely unknown.  
 
1.4.5.1 MIF in Parasitic Infections 
As described in previous chapters, MIF is released primarily by monocytes 
and macrophages (48). Once released, it modulates the expression and 
activation of several proinflammatory factors including cytokines, nitric 
oxide, COX2 and arachidonic acid. MIF prevents the activation-induced 
apoptosis mediated by the oxidative burst and p53 and thus sustains 
survival and proinflammatory function of macrophages (85). Interestingly, 
homologues of MIF have been found in a wide range of parasitic species 
such as the human parasitic nematodes Brugia malayi (86, 87) and 
Ancylostoma ceylonicum (88), in Plasmodium falciparum (89) and 
Plasmodium berghei (90), and in the tick species Amblyomma americanum 
(91). The homologues show remarkable similarity in both crystal structure 
and in vitro biological activity.  
 
1.4.5.2 MIF in Malaria 
Host MIF Functions 
 
Martiney et al. reported that ingestion of Plasmodium chabaudi-infected 
erythrocytes or malarial pigment (hemozoin) induces the release of MIF 
from macrophages. MIF has been shown to inhibit erythropoiesis in vitro 
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and elevated levels of MIF also were detected in BALB/c mice infected 
with P. chabaudi. Finally, the group demonstrated that serum levels of 
MIF correlated with disease severity (92). Highly increased MIF levels 
also were reported in the children and placenta of pregnant woman 
infected with P. falciparum (93). Infection of MIF knockout mice with P. 
chabaudi resulted in less severe anemia, improved erythroid progenitor 
development, and increased survival compared with wild type controls 
(94).  
Contradictory results were reported recently in a study investigating MIF 
transcripts in children with acute P. falciparum malaria. Circulating MIF 
levels were significantly lower in children with acute malaria relative to 
healthy, malaria-exposed children (95). In a follow up study, the group 
showed that children with prior mild malaria had higher plasma MIF 
levels than children with an identical number of previous episodes of 
severe malaria (96). These results suggest that increased basal MIF 
production may be important in generating immune responses that 
protects against the development of severe malaria.  
 
 
Parasite MIF Functions 
 
The MIF ortholog from P. berghei (PbMIF) was shown to be expressed in 
both a mammalian host and a mosquito vector and that, in blood stages, it 
is secreted into the infected erythrocytes and released upon schizont 
rupture. Mice infected with PbMIF-knockout parasites had significantly 
higher numbers of circulating reticulocytes. However, parasites lacking 
PbMIF were able to complete the entire life cycle and exhibited no evident 
changes in growth characteristics or virulence features during blood stage 
infection (90). 
The MIF ortholog of P. falciparum (PfMIF) also was shown to be expressed 
during the asexual blood stages of the parasite life cycle (89). Both 
Plasmodium MIF orthologs were characterized in vitro and were shown to 
possess tautomerase and oxidoreductase activities and to inhibit AP-1 
Introduction 
24 
 
activity in human embryonic kidney cells. Monocytes incubated with 
PfMIF displayed a decreased CD86, Toll like receptor (TLR) 2 and TLR4 
expression and showed reduced chemotactic response to monocyte 
chemotactic protein-1 (MCP-1). 
 
1.4.5.3 MIF in Leishmaniasis  
Host MIF Functions 
 
Several in vitro and in vivo studies have shown that MIF plays a critical 
role in mediating host resistance to Leishmania. Xu et al. (97) 
demonstrated that oral administration of MIF enhances resistance of 
BALB/c mice to L. major and Jüttner et al.  (98) went on to show that MIF 
mRNA and protein is up-regulated in lymph nodes of mice during the first 
week after infection with L. major and that MIF-mediated activation of 
macrophages to kill Leishmania is dependent on MIF’s ability to promote 
TNF-α and NO production. A study analyzing the course of cutaneous L. 
major infection in MIF gene-deficient mice further revealed that mif-/- mice 
were susceptible to disease and developed significantly larger lesions and 
greater parasite burdens than mif+/+ mice because of impaired macro-
phage leishmanicidal activity (99). 
 
Parasite  MIF Functions 
 
The genomic analysis of the Leishmania major genome has revealed two 
genes that exhibit significant sequence identity with the mammalian 
cytokine, macrophage migration inhibitory factor (100). The first charac-
terization of one of these orthologs, LMF1740 (LmMIF) was part the 
present work.  
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1.4.6 The Three-Dimensional Structure of MIF 
MIF consists of 114 amino acids and has a molecular weight of 12.5 kDa. 
The three-dimensional structure of human MIF has been determined 
independently by three groups in 1996 (101-103) showing MIF to 
crystallize as a trimer of three identical subunits. Each monomer consists 
out of a 4 stranded beta-sheet placed above two antiparallel alpha helixes. 
Two remaining beta-strands are part of intertwining loops and contribute 
to the stabilization of the trimer by forming interactions with β-sheets of 
adjacent subunits (Figure 6).  
 
 
       A.                                                        B.  
 
Figure 6. Three dimensional structure of MIF. (A) The human monomer and (B) 
trimer drawn from PDB entry 1MIF. The Figure was produced using Pymol (104) 
 
 
 
In contrast to the trimer determined by crystallography, studies involving 
ultracentrifugation, nuclear magnetic resonance (NMR), cross linking and 
size exclusion chromatography led to the conclusion that monomers, 
dimers and trimers exist in solution with monomers and dimers 
representing the major species in physiological concentrations (105-107). A 
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detailed re-examination of the oligomeric form using sedimentation 
equilibrium and sedimentation velocity studies indicates an unusually 
small partial specific volume of MIF and confirmed a strongly associated 
trimer at the tested concentrations above 10 μg/ml (108). Of note, these 
concentrations are ~5000 fold higher than MIF-serum levels measured 
from healthy individuals (109). However, the formation of the trimer is 
essential for the unexpected enzymatic activity of MIF. 
 
1.4.7 MIF, an Enzyme 
MIF exhibits a number of unusual features that distinguish this protein 
from typical cytokines. For instance, MIF possesses an enzymatic tauto-
merase/isomerase activity and a thiol-protein oxidoreductase activity. 
The tautomerase/isomerase activity is centered on the N-terminal proline 
that is invariant through all MIF homologs, including orthologs from 
parasite species like Leishmania major, Plasmodium falciparum and 
Ancylostoma ceylanicum.    
Physiologically relevant substrates have not yet been identified. However, 
several substrates have been described to be converted by MIF. The best 
studied substrates are 2-carboxy-2,3-dihydroindole-5,6-quinone (D-dopa-
chrome), a non-physiological molecule, which is tautomerized to 5,6-di-
hydroxyindol-2-carboxylic acid (DHICA) and the keto-enol isomerization of 
both p-hydroxyphenylpyruvate (HPP) and phenylpyruvate (110, 111) 
(Figure 7). The latter two substrates are involved in the metabolism of 
phenylalanine and tyrosine. High Michaelis constant values suggest, 
however, that reactions involving these substrates are unlikely to 
comprise a natural function for MIF (110). The tautomerase/isomerase 
activity requires the trimerization of MIF, because the active site is 
formed between subunits of the trimeric human MIF molecule as 
described for the substrate p-hydroxyphenylpyruvate (112). HPP interacts 
with Pro1, Lys32, and Ile64 from one subunit and Tyr95 and Asn97 from 
an adjacent subunit (Figure 7). 
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Figure 7. Tautomerase-reaction catalyzed by MIF. (A) Scheme of conversion of D-
dopachrome and (B) phenylpyruvate. (C) Interactions of MIF with the substrate HPP 
(112).  
 
 
The necessary low pKa for the function of Pro1 as the catalytic base in the 
reaction is given by its position in the hydrophobic cavity formed by these 
interacting residues. Solution NMR studies determined a pKa value of 5.6 
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for the nitrogen of Pro1, almost 4 pH units below the expected pKa for a 
nitrogen in a proline amid (113).  
In contrast, the thiol-protein oxidoreductase (TPOR) activity cannot be 
explained with the static trimeric structure of MIF. The basis of this 
enzymatic reaction is a CXXC-motif that spans from Cys57 to Cys60 (114). 
Unlike the tautomerase/isomerase active site, the TPOR activity is buried 
deep in the interface of two MIF-molecules and can therefore not be active 
in a trimer. MIF catalyzes the reduction of insulin, 2-hydroxyethyl-
disulfide, glutathione, and dihydrolipamide. (114). MIF shares this motif 
with a variety of enzymes of the TPOR family, including thioredoxin, 
protein disulfide isomerase and glutaredoxin (115). 
 
 
 
Figure 8. Schematic of oxidoreductase activities.  
 
 
Both enzymatic activities have been linked to MIF’s cytokine function. 
Amino acids 50-65 of the TPOR site of MIF are important for binding and 
modulation of the intracellular binding partner Jun activation domain 
binding protein (Jab1) (116, 117). Mutational studies of Pro-1 of the 
tautomerase active site showed that the mutant is defective in the 
neutrophil priming (113) and glucocorticoid counter-regulatory (118) 
activity of MIF. 
 
1.4.8 Small Molecule Inhibitors of MIF 
The observed connection of MIF tautomerase activity and biological 
function together with the ease of accessibility by enzymatic assays has 
raised the interest to the design of selective, low molecular weight MIF 
inhibitors to provide a potentially powerful approach to treat MIF-related 
diseases. Several small molecule inhibitors of MIF's enzymatic activity 
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have been developed and inhibitory effects on biological functions of MIF 
have been identified (Figure 9).     
 
            A.                         B.                              C. 
 
Figure 9. Small molecular MIF inhibitors. (A) N-(4-oxo-1-cyclohexa-2,5-dienylidene)-
acetamide (NAPQI), (B) (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid 
methyl ester (ISO-1) and (C) (E)- 4-hydroxybenzaldehyde O- cyclohexanecarbonyloxime 
(OXIM-11). 
 
 
(S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester 
(ISO-1), a competitive inhibitor of the tautomerase active site was shown 
to inhibit MIF-mediated glucocorticoid counter-regulatory activity and 
TNF-α release from cultured macrophages (54, 118). Furthermore, in vivo 
administration of ISO-1 demonstrated a protective effect in a mouse model 
of endotoxemia (54). Studies involving the inhibitor N-(4-oxo-1-cyclohexa-
2,5-dienylidene)acetamide (NAPQI) which forms a covalent adduct 
between NAPQI and MIF (119) and the competitive inhibitor (E)-4-
hydroxybenzaldehyde O-cyclohexanecarbonyloxime (OXIM-11) (120) 
further support the relationship between MIF’s catalytic activity and 
biological function. Despite these promising effects, universally high IC50s 
have limited the pharmacologic appeal of further developing existing small 
molecular MIF inhibitors. 
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2 Materials and Methods 
2.1 Equipment, Consumables and Chemicals 
2.1.1 Equipment 
Equipment Manufacturer 
Äktapurifier FPLC GE Healthcare, Piscataway, NJ 
Analytical balance AE163 Metller Toledo, Columbus, OH 
Beckman Avanti-J-E centrifuge Beckman, Fullerton, CA 
Biofuge pico centrifuge Heraeus Instruments, Hanau, 
Germany 
CO2 incubator VWR Scientific, Bridgeport, NJ 
CO2 incubator Heraeus Instruments, Hanau, 
Germany 
Confocal microscope LSM510      Zeiss, Thornwood, NY 
Electrophoresis power supply BioRad, Hercules, CA 
Eppendorf centrifuge  5415D Eppendorf, Westbury, NY 
FPLC-System Pharmacia, Uppsala, Sweden 
French Pressure Cell Press SLM Instruments, Rochester, NY 
French Pressure Cell Press Colora, Lorch, Germany 
Gen-Cycler PCR BioRad, Hercules, CA 
HisTrap Metal Chelate Affinity 
Column 
GE Healthcare, Piscataway, NJ 
HiTrap ion exchange columns GE Healthcare, Piscataway, NJ 
HPLC chromatography system Waters, Milford, MA 
Laminar Flow Hood Baker Company, Sanford, Me 
Light Microscope Olympus, Center Valley, PA 
Microscope Olympus CK40 Olympus Co GmbH, Hamburg, 
Germany 
Mosquito crystallization robot Molecular Dimensions Ltd, Apopka, 
FL 
pH-meter Corning, Lowell, MA 
Photometer UV-Visible Cary Varian, Darmstadt, Germany 
RAXIS-IV-Image Plate Detector Rigaku, Tokyo, Japan 
SDS-PAGE NuPAGE/XCell 
SureLock 
Invitrogen, Carlsbad, CA 
Sorvall RC5cPlus Thermo Scientific, Waltham, MA 
Spectrophotometer Infinite 200 Tecan, Männedorf, Switzerland 
Superdex 75 10/300 GL size 
exclusion column 
GE Healthcare, Piscataway, NJ 
Superdex 75 16/60 pg size exclusion 
column 
GE Healthcare, Piscataway, NJ 
Vacuum concentrator Bachhofer, Reutlingen, Germany 
Western-Blot NuPAGE/XCell II 
Blot Module 
Invitrogen, Carlsbad, CA 
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2.1.2 Consumables 
Consumable Manufacturer 
Amicon-, Microcon-, Centricon-,  and 
Centripep-filter devices 
Millipore Corporation, Bedford, 
MA 
Blotting paper Whatman, Clifton, NJ 
C8-SepPak Plus cartridge Waters, Milford, MA 
Cell culture equipment BD Falcon, Bedford, MA 
Cell culture equipment Greiner Labortechnik, 
Frickenhausen, Germany 
Cell culture insert, 8µm pore size BD Falcon, Bedford, MA  
Cell culture slides BD Falcon, Bedford, MA 
Eppendorf tubes 3810 Eppendorf, Westbury, NY 
NuPAGE 12% Bis-Tris-gels Invitrogen, Carlsbad, CA 
Polypropylene tubes BD Falcon, Bedford, MA  
Protein crystallization covers (96 well) Grace Bio Labs, Bend, OR 
PVDF membrane  Millipore Corporation, Bedford, 
MA 
Siliconized glass cover slides Hampton Research, Aliso Viejo, 
CA 
UV- Half Area Plate, 96 well Corning, Corning, NY 
 
 
2.1.3 Multi-Component Systems 
Kit Manufacturer 
Biotin Protein Labeling Roche, Indianapolis, IN 
Crystal Screen I Hampton Research, Aliso Viejo, 
CA 
Crystal Screen II Hampton Research, Aliso Viejo, 
CA 
PyroGene Recombinant Factor C 
Endotoxin Detection System 
Lonza, Walkersville, MD 
QIAprep MiniPrep Qiagen, Valencia, CA 
Qiagen Plasmid Maxi Kit Qiagen GmbH, Hilden, Germany 
SaltRX Crystal Screen Hampton Research, Aliso Viejo, 
CA 
SlowFade Antifade Invitrogen, Carlsbad, CA 
SuperSignal West Dura Pierce, Rockford, IL 
Wizard I Crystal Screen Emerald BioSystems, Bainbridge 
Island, WA 
Wizard II Crystal Screen Emerald BioSystems, Bainbridge 
Island, WA 
Wizard SV Gel and PCR Clean-Up 
System 
Promega, Madison, WI 
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2.1.4 Chemicals 
Chemical Manufacturer 
Acetonitrile J.T. Baker, Phillipsburg, NJ 
Agarose American Bioanalytical, Natick, 
MA 
Amino acids Sigma, St. Louis, MO 
Ammonium bicarbonate J.T. Baker, Phillipsburg, NJ 
Ampicillin Sigma, St. Louis, MO 
Bacto agar  BD, Franklin Lakes, NJ 
Bis-Tris-propane Sigma, St. Louis, MO 
Boric acid J.T. Baker, Phillipsburg, NJ 
Dextrose J.T. Baker, Phillipsburg, NJ 
DMEM Invitrogen, Carlsbad, CA 
DMEM Gibco, Eggenstein, Germany 
DNA ladder Invitrogen, Carlsbad, CA 
Dimethylsufoxide  Sigma, St. Louis, MO 
Dopachrome Sigma, St. Louis, MO 
DTT Sigma, St. Louis, MO 
Ethidium bromide Sigma, Munich, Germany 
Fetal bovine serum HyClone, Logan, UT 
Fetal bovine serum Gibco, Eggenstein, Germany 
Glucose Sigma, St. Louis, MO 
Glycerol Sigma, St. Louis, MO 
Glycine Fluka Chemie AG, Switzerland 
Histopaque-1077 Sigma, Munich, Germany 
H2O (HyPure, endotoxin free)  HyClone, Logan, UT 
p-hydroy-phenylpyruvat Sigma, St. Louis, MO 
L-3,4-dihydroxypehnylalanine methyl 
ester 
Sigma, St. Louis, MO 
Imidazole Sigma, St. Louis, MO 
Kanamycine Sigma, St. Louis, MO 
Luria Broth medium Invitrogen, Carlsbad, CA 
M9 Minimal Salts, 5x Sigma, St. Louis, MO 
Methanol Fisher scientific, Pittsburgh, PA 
β-Mercaptoethanol Sigma, St. Louis, MO 
Milk powder BioRad, Hercules, CA 
NHS-Fluorescein  Pierce, Rockford, IL 
p-nitrophenyl phosphate Sigma, St. Louis, MO 
NuPage LDS sample buffer Invitrogen, Carlsbad, CA 
NuPage SDS running buffer Invitrogen, Carlsbad, CA 
NuPage transfer buffer Invitrogen, Carlsbad, CA 
Penicillin/Streptomycin Gibco, Eggenstein, Germany 
Phosphate buffered saline, 10x Sigma, St. Louis, MO 
PIC-complete EDTA free Roche, Indianapolis, IN 
RPMI 1640 Gibco, Eggenstein, Germany 
Sodium acetate J.T. Baker, Phillipsburg, NJ 
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Sodium chloride J.T. Baker, Phillipsburg, NJ 
Sodium citrate Invitrogen, Carlsbad, CA 
Sodium hydroxide J.T. Baker, Phillipsburg, NJ 
Sodiumdodecylsulfate Sigma, St. Louis, MO 
Sodium m-periodate Sigma, St. Louis, MO 
Streptavidin-HRP Promega, Madison, WI 
Superblock buffer Pierce, Rockford, IL 
Texas Red-X phalloidin Invitrogen, Carlsbad, CA 
Tris American Bioanalytical, Natick, 
MA 
Tween-20 Sigma, St. Louis, MO 
Urea American Bioanalytical, Natick, 
MA 
 
 
2.2 Bacteria, Yeast, and Mammalian Cells 
2.2.1 Bacteria 
Strain Genotype Origin 
E.coli  
BL21(DE3) 
F- ompT hsdSB (rB-mB-) gal dcm rne131 
(DE3) 
Invitorgen, 
Carlsbad, CA 
E.coli 
DH5a 
F- mcrA Δ(mrr-hsdRMS-mcrBC)φ80lacZ 
ΔM15 ΔlacX74 recA1 araD139 
Δ(araleu)7697 galU galK rpsL (StrR) 
endA1 nupG 
Invitrogen, 
Carlsbad, CA 
E.coli M15 
[pREP4] 
 (Nals Strs rifs lacI  ara  gal  mtI F recA  
uvr+) 
Qiagen, 
Valencia, CA 
 
2.2.2 Yeast Cells 
Strain Genotype Origin 
AH109 MATa, trp1-901, leu2-3, 112, ura3-52, his3-
200, 
gal4Δ, gal80Δ, LYS2::GAL1UAS-
GAL1TATA-HIS3, GAL2UAS-GAL2TATA-
ADE2,URA3::MEL1UAS-EL1TATA-lacZ, 
MEL1 
Clontech 
Laboratories, 
Palo Alto, CA 
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2.2.3 Mammalian Cells 
Description Characterization Reference 
RAW 264.7 Macrophage; Abelson murine leukemia 
virus-transformed 
ATCC 
 
 
2.3 Plasmids and Primers 
2.3.1 Plasmids 
Plasmid Insert Description Resistance Reference 
pET22b PfMIF-HIS 
Bacterial 
expression 
Amp This work 
pET11b MIF Amp Lolis Lab 
pCRT7-NT-
TOPO 
PfMIF Amp Bucala Lab 
pCRT7-NT-
TOPO 
LmMIF Amp Bucala Lab 
pQE-30-uA HIS-CD74 Amp Lolis Lab 
pET22b p115-HIS  Bucala Lab 
pGBKT7 LmMIF 
Yeast two-
hybrid 
Kan This work 
pGBKT7 hMIF Kan This work 
pGADT7 LmMIF Amp This work 
pGADT7 hMIF Amp This work 
pGADT7 and pGBKT7 positive and negative control plasmids are from Clontech 
Laboratories, Palo Alto, CA. 
 
 
2.3.2 Primers 
hMIF-yeast-fw 5’-GGAATTCCATATGCGATGTTCATCGTAAACACC-3’ 
hMIF-yeast-rv 5’-CGGGATCCTTAGGCGAAGGTGGAGTTGT-3’ 
LmMIF-yeast-fw 5’-GGAATTCCATATGCCGGTCATTCAAACGTTTG-3’ 
Lm-yeast-rv 5’-CGGGATCCTTAGAAGTTTGTGCCATTCCAG-3’ 
PfMIF-fw 5’-CGCTAGACATATGCCGTGCTGCGAAGTG-3’ 
PfMIF-rv 5’-CCGCTCGAGGCCAAACAGGCTGCCGCATTTG-3’ 
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2.4 Media, Buffer and Solutions 
2.4.1 Media for Bacterial Culture 
 
LB-media 
   
Trypton 
 
10 g 
   Yeast extract 5 g 
   NaCl 10 g 
   H2O ad 1 L 
  For plates Bacto agar 10 g 
  For 
selection 
Ampicilin or 
kanamycin 
50 mg 
     
10x M9 media   Na2HPO4 60 g 
   KH2PO4 30 g 
   NH4Cl 10 g 
   NaCl 5 g 
   H2O ad 1 L 
 
 
2.4.2 Yeast Media 
 
YPD 
   
1% Bacto yeast extract                      
 
10 g 
   2% Bacto peptone 20 g 
   2% Dextrose                                       20 g
   2% Bacto agar                                   20 g 
   H2O add 1000 ml  
     
SD minium 
media 
2xAgar 
 
- autoclave 
- warm to   
   70°C 
4% Bacto agar in 
25mM HEPES, pH 6.8 
 
250 ml 
 Nutrient 
mix 
 
- sterile   
  filtrate 
- warm to      
   70°C 
10x YNB (67g/l)  
10x Glucose (200g/l) 
Amino acids 
50 ml 
50 ml 
As needed 
for selection 
   H2O add 250 ml  
  Mix 2x 
agar and 
nutrient 
mix 
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2.4.3  Cell Culture Media 
Media for PBMCs   Dulbecco’s RPMI  
   Penicillin 100 µg/ml 
   Streptavidin 100 µg/ml 
   L-glutamine 2     mM 
     
Media for RAW 264.7  DMEM  
  Penicillin 100 µg/ml 
  Streptavidin 100 µg/ml 
  L-glutamine 2     mM 
 
 
2.4.4 Buffers and Solutions 
If not indicated otherwise, all buffers and solutions were prepared in 
reagent grade water (ddH2O) 
 
2.4.4.1 General Buffers 
PBS, pH 7.4  NaCl 137  mM 
  KCL 2.7  mM 
  KH2PO4 1.5  mM 
  Na2HPO4 8.1  mM 
     
TAE-buffer (50x)   Tris-HCl, pH 8,5  2  M 
  Acetic acid 1  M 
  EDTA 100  mM 
     
     
TBS  Tris, pH 7.4 20  mM 
  NaCl 150  mM 
     
TBST  TBS   
  Tween-20 0.05 % 
     
Coomassie 
staining 
 Coomassie Brilliant Blue R-250 0.25 % 
  Methanol  40 % 
  Glacial acidic acid 10 % 
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2.4.4.2 Tautomerase Assay  
Dopachrome assay       
 Preparation of dopachrome*     
 L-3,4 dihydroxyphenylalanine methyl ester 4 mM 
Sodium m-periodate 8 mM 
      
 Working mixture    
 Potassium phosphate buffer, pH 7.4    40 mM 
 L-dopachrome 750 µM 
      
Hydroxyphenylpyruvate assay     
 Preparation of p-hydroxyphenylpyruvate (5 mM)**   
  18 mg of the crystalline free acid (enol)  18 mg 
  0.05 M acetate,pH 6 20 ml 
     
 Working mixture   
 Boric acid, pH 6.2 424 mM 
 p-hydroxyphenylpyruvate   750 µM 
*   Mix and incubate at RT for 5 min, then put on ice.  
** store at RT for 24 hours to tautomerize. It is then in the keto form and can be stored at 
4
◦
C for two  weeks. 
 
 
2.4.4.3 FPLC, HPLC and Refolding Buffers 
Protein Column Buffer   
LmMIF Q-Sepharose  Binding-buffer    
   Bis-Tris-propane, pH.6.8 30 mM 
   NaCl 20 mM 
  Elution-bufferI (salt gradient)   
   Bis-Tris-propane, pH.6.8 30 mM 
   NaCl 400 mM 
  Elution-buffer II (pH gradient)   
   Citric buffer, pH 5.5 20 mM 
   NaCl 20 mM 
      
PfMIF Q-Sepharose Binding-buffer I (pH gradient)   
   Tris-HCL, pH.8.5 20 mM 
   NaCl 10 mM 
  Elution-buffer I (pH gradient)   
   Bis-Tris-propane, pH.6.3 20 mM 
   NaCl 10 mM 
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PfMIF Q-Sepharose Binding-buffer II (salt gradient)   
   Tris-HCL, pH.8.0 20 mM 
   NaCl 10 mM 
  Elution-buffer II (salt gradient)   
   Tris-HCL, pH.8.0 20 mM 
   NaCl 500 mM 
      
PfMIF-HIS  
and p115728-
962 -HIS 
HisTrap- 
Nickel 
Affinity  
Binding buffer 
    Tris-HCl, pH 8 
    NaCl 
 
 50 
200 
 
mM 
mM 
   Imidazole 20  mM 
   β-mercaptoethanol 10  mM 
   Glycerol 10 % 
      
  Elution buffer   
   Tris-HCl, pH 8 50  mM 
    NaCl 200  mM 
   Imidazole 400  mM 
   β-mercaptoethanol 10  mM 
   Glycerol 10  % 
      
CD7473-232  Lysis buffer (French Press)   
   Tris-HCl, pH 8.0 20 mM 
   NaCl 150 mM 
   Imidazole 10 mM 
  Homogenization/Binding buffer   
   Imidazole, pH 9.0 10 mM 
   Urea 8 M 
   NaCl 150 mM 
  Elution buffer   
   Imidazole, pH 9.0 500 mM 
   Urea 8 M 
   NaCl 150 mM 
  Refolding buffer   
   Tris-HCl, pH 8.0 10 mM 
   NaCl 150 mM 
      
human MIF DEAE/Q-
Sepharose 
Loading/Elution buffer 
        Tris-HCL, pH.7.4 
 
20 
 
mM 
   NaCl 20 mM 
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2.5 Cell Culture Techniques 
 
Cells were cultured by routine protocols at 37°C in a humidified 
atmosphere with 5% CO2. When cells where > 80% confluent, adherent 
cells were detached from culture flask using Trypsin/EDTA, washed twice 
with PBS, and replated at 1:4 dilution.  
 
2.5.1 Isolation of PBMCs 
Blood was collected in a heparinized syringe and slowly layered on top of 7 
ml of Histopaque-1077 in a 15 ml colonial centrifuge tube. Following 
centrifugation at 400 x g for exactly 30 min at RT, the upper plasma layer 
to within 0.5 cm to the mononuclear cells containing opaque interface was 
carefully removed and discarded. PBMCs were transferred into a new 15 
ml conical tube, washed 3 times with PBS and resuspended in RPMI to 
1x106 cells/ml.   
 
2.5.2 Chemotaxis Studies 
Aliquots of PBMCs were placed in the upper chamber of a 24-well cell 
culture insert with 8 µm pore size (Falcon). In the lower chamber, MIF or 
LmMIF was placed following a 30 min pre-incubation with test 
compounds. Test compounds included the MIF inhibitors ISO-1 and 4-IPP 
or an N-terminal peptide of CXCR4 (CXCR41-27). After incubation for 3 
hours at 37°C, 5% CO2 transmigrated cells were methanol fixed, stained 
with Giemsa and counted under light microscopy. 
 
2.5.3 Cellular Uptake Studies 
Fluorescein labeling of LmMIF and MIF was performed with N-
hydroxysuccinimide (NHS)-fluorescein as described by manufacturer. For 
uptake studies, murine RAW264.7 macrophages cultured on glass cover 
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slides were incubated with fluo-MIF or fluo-LmMIF (1.5 µM) for 30 min at 
37°C. Cells were washed three times with PBS, three times with 50mM 
glycine/PBS, and then fixed for 20 min at 37°C with 3.7% 
formaldehyde/0.1% Triton-X/PBS solution. Actin staining was visualized 
with Texas Red-X phalloidin. 
 
 
2.6  Methods in Molecular Genetics/Biology 
2.6.1 Transformation of Bacteria 
Plasmid DNA was added to 50 µl of competent cells and incubated on ice 
for 30 min. The mixture was transferred to a water bath at 42°C for 45 sec 
and than placed on ice for 2 min. Subsequently, 400 µl LB medium were 
added and the cells were incubated at 37°C for one hour. This period 
allows the bacteria to recover and to begin to express antibiotic resistance. 
The medium was now spread onto selection plates and incubated 
overnight at 37°C to allow plaque formation. 
 
2.6.2 Plasmid-DNA Extraction from Bacteria 
Small amounts of up to 20 µg of plasmid DNA from a 5 ml overnight 
culture were purified according to manufactures instructions using 
Plasmid-DNA-Mini-Kit.  
 
2.6.3 Transformation of Yeast Cells (Yeast two Hybrid) 
Plasmid DNA was introduced into yeast by a modified lithium acetate 
method  (121). To produce competent cells, several fresh colonies (2 – 3 
mm in diameter) were inoculated in 1 ml YPDA, vortexed vigorously for 5 
min to disperse clumps and transferred into a flask containing 50 ml 
YPDA. The cells were incubated at 30ºC with shaking at 250 rpm to 
stationary phase (OD600>1.5; 14 – 18 hours). 30 ml of the overnight culture 
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then were diluted in a flask containing 300 ml YPDA to an OD600 of 0.2 – 
0.3. After shaking the cells for another 3 h, the cell-suspension with an 
OD600 of 0.4 – 0.6 was centrifuged at 1000 x g for 5 min, washed with 
sterile H20 and resuspended in 1.5 ml freshly prepared 1x TE/LiAc.   
For the transformation, 0.1 ml of the competent cells were mixed with 0.1 
mg herring test carrier DNA and 0.1 mg plasmid DNA followed by 
vortexing with 0.6 ml PEG/LiAc solution. The mixture was incubated at 
30ºC for 30 min with shaking, 70 µl DMSO were added and the heat shock 
was done for 15 min in a 42ºC water bath. Cells were chilled on ice, 
pelleted (5 sec; 14000 rpm), resuspended in 0.5 ml TE buffer and spread 
on SD agar plates that selected for desired transformants.  
 
2.6.4 Agarose Gel Electrophoresis 
To analyze and isolate DNA according to its mass, agarose gel 
electrophoresis was carried out. DNA was applied to a gel of 1% 
agarose/TAE and separated at 100 V. The DNA was visualized in the gel 
by addition of ethidium bromide under UV light. 
 
2.6.5 Isolation of DNA from Agarose Gels 
DNA bands from PCR or restriction reactions were purified from agarose 
gels using Wizard SV Gel and PCR Clean-Up System according to 
manufacturer’s  instructions.  
 
2.6.6 Digestion of DNA with Restriction Enzymes  
1 ug of purified DNA was incubated with 1 U of restriction enzyme and a 
corresponding buffer for 2 – 4 hours at 37°C. To assess complete digestion, 
the fragments were separated by agarose gel electrophoresis. 
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2.6.7 Ligation of DNA fragments 
Purified DNA fragments were mixed in a molar ratio of 1:3 vector/insert 
with 40 U of T4-DNA ligase and T4-ligase Buffer in a 20 µl reaction. The 
reaction was incubated at 16°C over night or at room temperature for 3 
hours. 
 
2.6.8 Determination of DNA Concentration 
The concentration and purity of DNA/RNA was determined by 
photometric analysis. Nucleic acids absorb light with an absorption 
maximum at 260 nm wavelength with an average extinction coefficient of 
0.020 (µg/ml)-1 cm-1 for double stranded DNA. Thus an optical density of 1 
corresponds to a concentration of 50 µg/ml. 
The ratio between OD260 vs. OD280 assesses the purity of the sample with 
respect to protein contamination. A quotient of 1.8 to 2.0 indicates an 
optimal sample.   
 
2.6.9 PCR 
Template DNA was amplified by Polymerase chain reaction. The PCR 
program and the concentrations of the components of a typical PCR 
reaction are listed in the table below.  
 
Component Concentration PCR-program 
  Step T (°C) t (s) repeats 
DNA-template 20 ng -1 µg Denaturation 95 5  
Primer-forward 1 µM Denaturation 95 1  
Primer-reverse 1 µM Annealing 55-65 1 35 
Polymerase-Buffer 1x Polymerisation 72 2  
dNTP-mix 0.3 mM Cooldown 4 10  
Polymerase 0.05 U/µl     
ddH2O ad 50 µl     
 
Materials and Methods 
43 
 
2.7  Methods of Protein Biochemistry 
2.7.1 Protein Expression  
Cloned DNA constructs were transformed into the E.coli strain Bl21(DE3) 
or M15(pREP4), respectively. E.coli cells containing the expression vector 
were grown overnight at 37°C in Luria Broth supplemented with 
appropriate antibiotics. The next morning, fresh media was inoculated 
with the preculture (1:20) and cells were grown to an OD600 of 0.6 to 0.8, 
induced with 1mM IPTG and harvested 4 hours later. 
For the production of selenomethionated protein, cells from the preculture 
were harvested and washed with PBS. The cells then were used to 
inoculate Minimal media lacking Gly, Ala, Pro, Asn, Cys and Met and 
grown to an OD600 of 0.5 to 0.6. Per liter of culture, 100 mg of Thr, Lys, 
and Phe; 50 mg of Leu, Ile, and Val; and 60 mg of L-SeMet was added as 
solid powder. The temperature then was changed to 30°C, the protein 
expression was induced with 1 mM IPTG and the cells were harvested the 
next morning.  
 
2.7.2 Purification of Proteins 
2.7.2.1 Purification of Native Sequence LmMIF 
Recombinant, native sequence LmMIF protein was produced by expression 
from the pCRT7/CT-TOPO E. coli plasmid, with the inserted sequence 
engineered with a 3’ stop codon to prevent expression of the V5-His 
carboxy terminal tag in E.coli (DE3) cells. 
Cells were harvested by centrifugation, washed two times in lysis buffer 
(30 mM Bis-Tris (pH6.8), 20 mM NaCl) and resuspended at 2.5% of the 
original volume of growth medium. Cells were lysed in the presence of 
protease inhibitor cocktail using a French Press. Soluble proteins were 
collected by centrifugation at 16 rpm for 25 min. The filtered supernatant 
was applied to a Q-Sepharose Fast Flow column previously equilibrated 
with lysis buffer. Unbound proteins were washed out of the column using 
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lysis buffer. LmMIF was eluted in a salt gradient (elution buffer A: 30 mM 
Bis-Tris (pH 6.8), 400 mM NaCl). LmMIF-containing fractions than were 
pooled and dialyzed against lysis buffer. For the second purification step, 
the sample was re-loaded on the Q-Sepharose column equilibrated with 
lysis buffer and eluted by applying a pH gradient towards 20 mM citric 
buffer (pH 5.5), 20 mM NaCl. The residual impurities were removed in a 
third step by gel filtration over a Superdex 75 column (HiLoad 16/60) with 
30 mM Bis-Tris (pH 6.8), 20 mM NaCl. 
 
2.7.2.2 Purification of Native Sequence PfMIF 
PfMIF was expressed and purified from pCRT7/CT-TOPO E. coli plasmid 
in a similar fashion than LmMIF with the following differences. The 
harvested cells were resuspended and lysed in 20 mM Tris (pH 8.5), 10 
mM NaCl. The soluble protein fraction than was loaded on a Q-Sepharose 
Fast Flow column and eluted with a linear pH gradient to 20 mM Bis-Tris 
(pH 6.3), 10 mM NaCl. After rebuffering the PfMIF-containing fractions to 
20 mM Tris (pH 8.0), 10 mM NaCl and reloading on the Q-Sepharose 
column the protein was eluted with a liner salt gradient towards 20 mM 
Tris (pH 8), 500 mM NaCl.  
 
2.7.2.2.1  Endotoxin Removal from LmMIF and PfMIF  
MIF has an unusually high affinity for endotoxin that must be removed to 
ensure that lipopolysaccharide (LPS) does not interfere with the results of 
the biological assays. To ensure a low endotoxin content, all buffers used 
for purification were prepared using endotoxin-free HyPure Cell Culture 
Grade Water (<0.005 EU/ml; HyClone). Columns were treated in 3 cycles 
with 2 column volumes of 1 M NaOH followed by 2 column volumes of 
pyrogen-free water. The resulting MIF preparations contained <20 pg 
LPS/µg protein as determined by the PyroGene Recombinant Factor C 
assay (Cambrex BioScience).   
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2.7.2.3 Purification of Human MIF 
Human MIF was produced by expression from the pET11b E.coli plasmid. 
Cells were harvested, lysed by French press in 20 mM Tris (pH 7.4)/20 
mM NaCl. Soluble proteins were collected by centrifugation. The filtered 
lysate then was applied to a DEAE-Sepharose anion exchange column 
serially connected to a SP-Sepharose cation exchange column equilibrated 
with 20 mM Tris (pH 7.4), 20 mM NaCl. Under these buffer conditions, 
most contaminating proteins bind one of the chromatographic media, 
whereas human MIF does not. The MIF-containing fractions were pooled 
and concentrated. The residual impurities were removed by gel filtration 
over an S-75 column (HiLoad 16/60 Superdex 75) 
 
2.7.2.3.1 Endotoxin Removal from Human MIF  
For removal of LPS from huMIF, approximately 2 mg of purified protein 
was applied to reversed phase chromatography on a C8-SepPack column 
activated with methanol and then washed with low endotoxin water.  The 
bound protein was washed with pure water and 30% acetonitrile and 
eluted with 60% acetonitrile. The samples were kept at -80 °C until 
lyophilization. For refolding, lyophilized pellets of MIF were dissolved in 
350 µl of 8 M urea and incubated for 1 hour. Four microliters of 1 M DTT 
was added and the solution was incubated for an additional hour at RT. 
Three consecutive times, 350 µl of 10 mM DTT were added, the contents 
were swirled, and the tube was incubated at room temperature for 30 min. 
The solution was then incubated at 4 °C for 30 min and subsequently 
centrifuged at 14,000 rpm for 10 min at 4 °C. The protein was dialyzed at 
4 °C against 10 mM dithiothreitol in Tris-buffered saline, pH 7.4 using a 
dialysis Slidealyzer cassette (Pierce) MWCO 7,000 overnight followed by 
dialysis against Tris-buffered saline over the next several days.  
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2.7.2.4 Purification of Histidine-tagged p115728-962 and PfMIF  
p115 or PfMIF were produced by expression from the pET22b E. coli 
plasmid, with the inserted sequence engineered to produce a C-terminal 
histidine fusion protein. Pelleted bacteria were resuspended in binding 
buffer (50 mM Tris (pH 8.0), 20 mM imidazole, 10 mM β-mercaptoethanol, 
200 mM NaCl, 10% Glycerol) and lysed by French Press. The crude 
bacterial extract was purified using a HisTrap FF nickel chelating column 
with a linear gradient of 20 – 400 mM imidazole/ binding buffer. The peak 
fractions, as determined by SDS-PAGE, were subjected to gel filtration 
chromatography.   
 
2.7.2.5 Purification of CD7473-232  
CD7473-232 was expressed from a pQE-30uA E.coli expression vector 
engineered to produce a 6xHis-tagged N-terminal fusion-protein. Given 
the instability of this protein, it is necessary to work quickly and to keep 
the protein on ice or at 4°C. It also was essential to use 0.1 mM PMSF in 
all steps. Pelleted cells were resuspended in lysis buffer (20 mM Tris (pH 
8.0), 150 mM NaCl, 10 mM imidazole) and lysed using a French press. 
CD74 inclusion bodies were separated by centrifugation at 18000 X g for 
25 min. The pelleted proteins were resuspended in binding buffer (10 mM 
imidazole (pH 9.0), 8 M Urea, 150 mM NaCL), homogenized using a 
dounce homogenizer, filtered and loaded on a HisTrap FF nickel chelating 
column equilibrated with binding buffer. CD7473-232 was eluted using a 
gradient against elution buffer (500 mM imidazole/ binding buffer). The 
CD7473-232-containing peak was then pooled and slowly dialyzed against 
refolding buffer (10 mM Tris (pH 8.0), 150 mM NaCl). At this step, a 
breakdown product of CD7473-232 might be detectable by SDS-page analysis 
which can be removed by reversed phase HPLC using a C4 column. The 
protein is loaded on the column using 0.1% TFA/H2O and eluted with a 
linear gradient against 0.1% TFA/Acetonitrile, pooled and refolded.   
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2.7.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Proteins were boiled for 10 min in LDS sample loading buffer to produce a 
linear polypeptide chain coated with negatively charged LDS molecules. 
Proteins then were separated according to their size in Bis-Tris 12% 
polyacrylamide gels (Lammli 1970) at 180 V in a NuPAGE/XCell SureLock 
chamber.  
 
2.7.4 Coomassie Staining 
Coomassie Blue staining is based on the binding of the dye Coomassie 
Brilliant Blue R250, which binds basic amino acids. Polyacrylamide gels 
were incubated in Coomassie staining solution. To visualize the proteins, 
the gel was microwaved in dH2O three to five times for 2 minutes.   
 
2.7.5 Competition Binding Assay 
The binding of LmMIF to recombinant, soluble CD74 ectodomain 
(sCD7473–232), the C-terminal region of the Golgi-associated binding 
protein p115 (p115702-962 ) or the N-terminal region of CXCR4 (CXCR41-27), 
respectively was studied by coating individual wells of a 96-well plate with 
these proteins as described by Leng et al. (55). Plates were washed 4 times 
with TBST (pH 7.4) and blocked with Superblock buffer for two hours at 
room temperature. Human MIF was biotinylated and added at 2 µg/ml in 
triplicate wells with increasing concentrations of human MIF or controls. 
Incubation was continued at room temperature for 2 hours followed by 
washing with TTBS (pH 7.4). The bound, biotinylated hMIF was detected 
by adding streptavidin-conjugated alkaline phosphatase for 1 h, followed 
by washing and detection with p-nitrophenyl phosphate. The OD405 was 
measured and values plotted as percent OD405 relative to wells containing 
biotinylated human MIF alone. Each plot represents at least three 
independently performed assays, and each data point depicts a SEM 10%.  
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2.7.6 BIAcore Analysis 
The real-time binding interaction of LmMIF or PfMIF with sCD7473–232 
measured by surface plasmon resonance was carried out by Chen Y, 
Kwong YK, Xiong H, and Zhang B (Mt. Sinai School of Medicine, NY) 
using a BIAcore 2000 optical biosensor (BIAcore) as previously described 
(55). Briefly, sCD7473–232 was diluted in 10 mM sodium acetate (pH 5.2) at 
1 µmol. Fifty microliters of a N-hyrdoxysuccinimide and N-ethyl-N-
(dimethyaminopropyl)carbodiimide mixture was injected at a speed of 2 
µl/min for 25 min, followed by injection of 50 µl of 1 µM purified sCD7473–
232. Once the surface plasmon resonance reached 10,000 U, the injection 
was stopped, and the active amine sites were blocked with 35 µl of 1 M 
ethanolamine (pH 8.5). The immobilized CM5 chip was washed overnight 
with 1x PBS at 20 µl/min. The derived sensor chips were washed and 
equilibrated in HEPES or PBS (pH 8.0; 20 µl/min) and the ligand (LmMIF 
or PfMIF) was introduced at five serial dilutions in BIAcore buffer (1 mM 
DTT, 2.5 mM MgCl2, 20 mM HEPES, 1 mM EDTA, 150 mM NaCl, 0.005% 
P20) in 60 – 100 µl injection volumes at a flow rate of 20 µl/min. Binding 
was measured at 25°C for 5 min, followed by 15 min of dissociation. Sensor 
chip regeneration was performed for 1 min with 1 M NaCl, 50 mM NaOH. 
The whole process was repeated three times for each dilution sample. 
Sensorgram response data were analyzed in the BIA evaluation kinetics 
package and the equilibrium binding constants calculated. 
 
2.7.7 Determination of Protein Concentrations 
Protein concentrations were determined by measuring absorbance at 280 
nm. Extinction coefficients were estimated using the following equation: 
Equation 1: 
 
ε280= Numb(Tyr)*ε280(Tyr)+Numb(Trp)*ε280(Trp)+Numb(Cysteine)*ε280(Cystine) 
Where: ε280 (Tyr) = 1490, ε280 (Trp) = 5500, ε280 (Cys) = 125 
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Protein  Extinction Coefficient [M-1 cm-1] 
huMIF 13688 
LmMIF 10095 
PfMIF 7700 
CD7473-232 19480 
 
Protein concentration of p115702-962, which does not possess significant 
absorbance at 280 nm was measured by Bradford according to 
manufacturer’s instructions.   
 
2.7.8 D-Dopachrome Tautomerization Assay  
The model MIF substrate, D-dopachrome methyl ester (2.4 mM), was 
prepared as described previously. Tautomerase activity was determined at 
room temperature by adding a final concentration of 0.75 mM dopachrome 
methyl ester (ε=3700 M-1cm-1) to a 96-well plate containing human MIF or 
LmMIF in 40 mM potassium phosphate buffer (pH 7.4). The inhibitory 
effect of ISO-1 or 4-IPP was determined by pre-incubating LmMIF or 
human MIF with inhibitor for 30 mins prior to addition of the substrate. 
The initial velocity of the MIF-mediated conversion of D-dopachrome 
methyl ester to indole carboxylic acid methyl ester was measured for 30 
sec at λ=475 nm and the specific activity expressed as converted 
dopachrome in mM/min/µM of protein. 
 
2.7.9 Mass Spectrometry 
Recombinant proteins were analyzed by electrospray using a C-4 capillary 
column and a Q-Tof Micro mass spectrometer at the Proteomics and Mass 
Spectrometry Resource of the Yale Keck Laboratory. Solvent A was 5% 
acetonitrile, 0.1% formic acid and 0.02% trifluoroacetic acid. Solvent B 
consisted of 95% acetonitrile, 0.1% formic acid and 0.02% trifluoroacetic 
acid. The flow rate was 5µL/min. The mass measurement accuracy of this 
instrumentation was ± 0.01–0.02%. 
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2.7.1 Steady-State Fluorescence Spectroscopy 
In titration experiments, 2.5 µM LmMIF and various concentrations of 
CXCR41-27 (0-30 µM) were mixed. Fluorescence intensity was monitored at 
an excitation wavelength of 288 nm and an emission range of 320-360 nm. 
Non-linear fitting to an equation describing MIF-CXCR41-27 equilibrium 
was used to determine the dissociation constant. 
 
2.7.2 NMR-Experiments 
Samples for NMR spectroscopy contained 300 µM 15N-MIF and 600 µM 
CXCR41-27 in 8% D2O/PBS. 1H15N-HSQC experiments were carried out at 
25 °C in a Varian INOVA 600MHz spectrometer with a 5-mm triple 
resonance probe equipped with a triple-axis (XYZ) pulsed magnetic field 
gradient. All pulse sequences were taken from the Varian BioPack user 
library. Spectra were processed and analyzed using the programs nmrPipe 
(122) and Sparky (123). Assignment of resonance peaks for MIF was based 
on a previously published resonance assignment (107). 
 
2.8  Methods of Structural Biology  
2.8.1 Protein Crystallization 
For protein crystallization, the purified proteins were concentrated using 
Amicon Ultra Centrifugal Filters with a 5 kDa cutoff. All crystals were 
obtained by the hanging drop vapor diffusion method at 18 °C. Drops were 
prepared by combining equal volume of protein solution and reservoir 
solution. 
Initial crystallization trials were performed using different protein 
concentrations on a Mosquito crystallization robot in a 96-well plate 
format using the standard Hampton and Wizard screens. Refinement 
screens were done in 24-well plates using the hanging drop vapor diffusion 
method with a drop composition of 1 μl protein and 1 µl well solution.  
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2.8.2 Data Collection of LmMIF 
For data collection, the crystals were cryoprotected in the reservoir 
solution with 20% glycerol. Diffraction data were collected at beamline 
X29A in the Brookhaven National Laboratory (BNL). Multiple wavelength 
anomalous diffraction (MAD) data with a selenomethionylated crystal 
were collected at three different wavelengths (0.97912 Å, 0.97928 Å and 
0.96389 Å) and a single wavelength data with a native crystal was 
collected at 0.95 Å to a resolution of 1.03 Å. The data were indexed at the 
space group R3 (a=b=52.3 Å, c=96.8 Å) and scaled using HKL2000 (124). 
 
2.8.3 Structure Determination of LmMIF 
Intensity conversion to structure factor amplitudes was carried out with 
SCALA in the CCP4 program package. Initial attempts to solve the 
structure by the Molecular Replacement method were unsuccessful 
because of low sequence identity with the human MIF search models 
(21%). 
The three-dimensional structure of LmMIF was solved using the Multi-
Wavelength Anomalous Dispersion method (MAD). The initial phase was 
determined using HKL2MAP (125). The MAD dataset was analyzed with 
SHELXC and the heavy atom substructure was determined with 
SHELXD. The phase problem was solved with SHELXE and SHELXD 
found a solution containing 3 selenium sites in the asymmetric unit of the 
crystal structure. The human MIF structure (101) was used as a template 
to build an initial LmMIF model using XTALVIEW (126). The model was 
refined against the native data using REFMAC (127) and CNS (128) 
followed by SHELX-97 (129). XTALVIEW was used to visualize the 
structure and to make manual adjustments of the coordinates to improve 
their agreement with the electron density map. Crystallographic data 
collection and refinement statistics are listed in Table 4. The coordinates 
of the LmMIF structure have been deposited with the Protein Data Bank 
under accession code 3B64.  
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Because the electron density could not be seen, the sidechain of residue 4 
is absent in the final model.  
 
2.8.4 Data Collection of Human MIF◦4-IPP Complex 
Data were collected in house using a Rigaku RAXIS-IV imaging plate area 
detector. The crystal was cryo-protected in the reservoir solution 
containing 25% glycerol. Diffraction data were collected at –180 °C and 
integrated and scaled by HKL2000 (15) to 1.8 Å.  
 
2.8.5 Structure Determination of Human MIF Complexed with 
4-IPP 
The structure was solved by molecular replacement with Phaser (130) 
using the structure of MIF in complex with Oxim-11 as search model 
(120). Refinement was performed using CNS and Refmac (127, 128) and 
manual manipulation of the model was done using MIFit 4.1. The 
structure is available from the RCSB Protein Data Bank and has been 
assigned the RCSB ID code RCSB045257 and PDB ID code 3B9S. 
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3 Specific Aim 
The aim of this thesis was the biochemical, biological and structural 
characterization the MIF orthologs from the protozoan parasitic species 
Leishmania major and Plasmodium falciparum. This work addressed 
whether the parasitic proteins have the potential to mimic or to interfere 
with the host homologue and thus play a potential role in the diverse 
immune evasion strategies employed by these parasites.   
To achieve this goal, purification procedures for the parasitic MIF proteins 
had to be established and structural studies were aimed to elucidate 
whether the sequence similarity of the parasitic proteins extends to its 
three-dimensional structure.    
In order to accomplish immune evasion, the parasitic proteins should at 
least interact with some of the host MIF binding partners. Therefore, 
known intracellular and extracellular interaction partners of the human 
MIF protein were purified and analyzed for direct interaction via ELISA-
based competition assays, surface plasmon resonance spectroscopy, 
steady-state fluorescence spectroscopy and nuclear magnetic resonance 
spectroscopy.  
Cell migration, ERK1/2 MAP kinase activation and inhibition of apoptosis 
are important immunological functions linked to MIF.  To study whether 
the parasitic proteins can mimic or block some of these biological 
characteristics could further support their role in immune evasion.  
Finally, small molecular inhibitors aimed at the tautomerase active site of 
MIF were shown to block its biological function. However, therapeutic 
interest of existing inhibitors is limited due to low binding affinity; more 
potent inhibitors are desired.  Therefore, an additional aim of this thesis 
was the characterization of a new, prototypic human MIF inhibitor by 
crystallographic methods. Furthermore, it was of interest to investigate 
the potency of existing human MIF inhibitors on their parasitic 
counterparts for a future development of specific, parasitic MIF inhibitors.   
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4 Results 
4.1 Structure Determination of Human MIF in Complex 
with the Novel Active Site Inhibitor 4-IPP 
 
4.1.1 Crystallization of Human MIF Complexed with 4-IPP 
MIF possesses an unusual ability to catalyze the tautomerization of the 
non-physiological substrates D,L-dopachrome methylester into their 
corresponding indole derivates (111). Numerous studies have shown the 
importance of this enzymatic active site for the biological activities of MIF 
(54, 113, 118, 120). Targeting this site with high affinity inhibitors could 
provide improved biologic inhibitory activities against MIF.  
Using a computational virtual screening strategy, 4-iodo-6-phenyl-
pyrimidine (4-IPP) was identified as a small molecule inhibitor of human 
MIF by Bob Mitchell and colleagues (Figure 10). Preliminary studies 
performed by this group showed that 4-IPP forms a covalent modification 
of the MIF protein and inhibits the tautomerization activity with a ~ 5 – 
10 times higher potency than the current described  inhibitors (118-120).  
 
 
Figure 10.  Structure of the small molecule MIF inhibitor 4-iodo-6-
phenylpyrimidine. 
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To determine the site of interaction of 4-IPP with MIF, crystallographic 
studies were performed. For crystallization trials, a dilution-incubation-
concentration strategy was used. MIF diluted to 0.1 mM (in 20 mM Tris 
(pH 7.4), 20 mM NaCl) was mixed with a 10-fold molar excess of 4-IPP 
(diluted to 1 mM in DMSO) followed by incubation overnight at room 
temperature to allow formation of the covalent complex. Using a 3 kDa 
cut-off filter unit, the mixture was concentrated 10-fold to a final 
concentration of 1 mM protein. This dilution-concentration step allowed 
washing out the unbound inhibitor and more importantly, the DMSO 
concentration was reduced to a concentration acceptable for crystallization 
trials. Prior to co-crystallization trials, the formation of the complex was 
confirmed by mass spectroscopy revealing that the co-incubation of MIF 
with 4-IPP results in a mass increase of 154 kDa. Because 4-iodo-6-
phenylpyrimidine has a molecular weight of  282 kDa and the iodine at 
position 4 of the pyrimidine ring can act as a leaving group, the increased 
mass of 154 kDa was the expected result of a covalent modification of MIF 
by de-iodinated 4-IPP.  
 
Figure 11. Mass spectroscopy analyses of 4-IPP modification of MIF. MIF was 
incubated either with DMSO alone (top panel) or 4-IPP (bottom panel).  
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Crystallization trials performed in 96-well plate formats with available 
crystallization screens were unsuccessful. However, the complex was 
crystallized using a crystallization condition established for the co-
crystallization of MIF with ISO-1 (2 M ammonium sulfate, 4% isopropa-
nol, 0.1 M Tris (pH 7.5) (112)).  Equal volumes of the MIF◦4-IPP complex 
and reservoir solution were mixed to form 3 µl drops. Out of several trials 
only one orthorhombic crystal appeared after about 2 weeks with size 
dimensions of approximately 300 x 250 μm (Figure 12). 
The crystal obtained under this condition was used to measure diffraction 
data leading to structure determination. The data of the crystal were 
collected in house using a Rigaku RAXIS-IV imaging plate area detector 
and diffracted to 1.80 Å. The crystal belonged to the space group P212121 
with unit cell parameters of a=67.89 Å, b=67.9 Å, c=88.30 Å and 
α=β=γ=90°. Data collection and refinement statistics are listed in Table 3. 
 
 
 
Figure 12. Crystal and diffraction pattern of the MIF◦4-IPP complex. The crystal 
(top) diffracted to 1.80 Å (bottom).  
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Table 3. Data collection and refinement statistics. 
  
Data collection  
Space group P212121 
Cell dimensions  
    a, b, c (Å) 67.89, 67.90, 88.30 
    α, β, γ () 90, 90, 90 
Wavelength (Å) 1.54 
Resolution (Å)* 50-1.8 (1.86-1.80) 
Rsym or Rmerge 0.062 (0.496) 
Average I / σI 21.0 (2.7) 
Completeness (%) 97.4 (96.3) 
Redundancy 4.5 (4.3) 
  
Refinement  
Resolution (Å) 50-1.8 
No. reflections 37563 
Rwork / Rfree 0.197/ 0.23 
Average B factors (No. of atoms)  
    Overall 25.67 (2916) 
    Protein 24.28 (2625) 
    Inhibitor 34.11 (36) 
    Water 33.52 (217) 
    Sulfate 88.41 (20) 
    Glycerol 47.35 (18) 
R.m.s deviations  
    Bond lengths (Å) 0.016 
    Bond angles () 1.445 
Ramachandran plot (%)**  
    most favored 91.0 
    allowed 9.0 
*Highest resolution shell is shown in parenthesis.  
**As defined in PROCHECK 
 
 
 
4.1.2 The Three-Dimensional Crystal Structure of the MIF◦4-
IPP-Complex 
The crystal structure of the MIF◦4-IPP complex was solved at 1.8 Å and 
contained the MIF trimer in the asymmetric unit. As expected from the 
inhibitory effect on the tautomerization, the small molecular inhibitors 
were located deep in the tautomerization active site of MIF, where each 
monomer was complexed with one 4-IPP molecule. As shown in Figure 13, 
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4-IPP binds covalently to MIF at the nitrogen of the N-terminal proline by 
substitution of the iodo group at the 4-position of 4-IPP.  
                  
                         A. 
 
                               B. 
 
Figure 13. Co-crystallization of MIF and 4-IPP. (A) Fo-Fc 'omit' electron density map 
contoured at 3.0 σ of the MIF◦4-IPP complex (grey wire mesh) calculated with phases 
from the model in which Pro1 and 6-phenylpyrimidine were omitted. 6-phenylpyrimidine 
(orange) with its covalent bond to Pro-1, as well as Met A2 and Tyr B95 are represented 
as sticks. (B) Connolly surface of MIF colored by CPK colors with the covalently bound 6-
phenylpyrimidine adduct shown in stick representation (PDB entry: 3B9S). Figures were 
prepared by using PyMOL (104) 
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In addition to this important covalent bond, structural analysis revealed 
that there is a hydrophobic interaction that exists between the inhibitor 
and the side chains of the amino acid residues within 2.5 Ångstroms (with 
hydrogens): Met A2, Tyr A36, His A62, Val A106, Phe A113, and Tyr B95. 
The phenyl substituent is oriented deep in the MIF catalytic pocket near 
Met A2 (Figure 13). This is similar to existing crystal structures of MIF 
with antagonists 7-hydroxy-2-oxo-chromene-3-carboxylic acid ethyl ester 
(131) and OXIM6 (120) although the phenyl substituent of bound 4-IPP is 
located slightly deeper into the binding pocket and in a different 
orientation. There is some apparent freedom of rotation of the phenyl ring 
as two different conformations exist in the tri-substituted trimeric MIF 
crystal structure.  
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4.2  The Parasitic MIF Orthologs from Leishmania 
major and Plasmodium falciparum 
 
In this section, the purification and functional characterization of the MIF 
orthologs from L. major (LmMIF) and P. falciparum (PfMIF) are de-
scribed.  Both orthologs were hypothesized to play a role in the immune 
evasion of the parasites. 
   
4.2.1 Sequence Alignment of LmMIF, PfMIF, and Human MIF  
An amino acid sequence alignment of three selected members of the MIF 
protein family was prepared using the T-Coffee multiple sequence 
alignment program. The alignment then was subjected to ESPript 2.2 for 
secondary structure and hydropathic character assignment (Figure 14); for 
comparing the structures and features of the different proteins, residue 
numbering for this and the following sections is based on this sequence 
alignment of the different structures. Altogether, there are 11 invariant 
residues in MIF (Pro1, Pro12, Leu21, Gly34, Lys35, Pro36, Phe52, Gly54, 
Gly68, Gly69, Arg96 and Phe116). Human MIF is distinguished by the 
presence of three conserved cysteines (Cys59, Cys62, and Cys83), Cys59 
and Cys62 define a CXXC motif that mediates thiol-protein oxidoreductase 
activity (114, 117) and Cys83 is suggested to be essential for the in vivo 
association between MIF and p53 (132). These conserved cysteines are 
absent in the Leishmania major and Plasmodium falciparum sequences. 
The MIF N-terminal proline (Pro1) by contrast is universally conserved. 
Proline-1 functions as a catalytic base in the tautomerization of model 
substrates, and it has been shown by X-ray crystallography studies of the 
mammalian proteins to reside within a hydrophobic, substrate-binding 
pocket (112, 133, 134). Despite the low sequence identity of LmMIF and 
PfMIF to human MIF (21 and 27 percent, respectively), conservation of 
residues of the tautomerase active site is obvious as residues implicated in 
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substrate contact (112) are predominantly found to be highly invariant. 
Moreover, the overall pattern of hydropathy remains widely conserved 
(Figure 14). 
 
 
Figure 14. Amino acid sequence alignment. Selected MIF molecules were aligned 
with the program T-Coffee (135). The figure including secondary structure assignment 
(PDB-entry 1MIF) and the hydropathic character was generated using the program 
ESPript 2.2. Residues marked with solid red boxes indicate complete conservation; 
residues with similarity are labeled in red. Hydropathy for each of the proteins is 
rendered by the bars bellow the alignment. Pink is hydrophobic, cyan is hydrophilic. The 
symbol ▲ identifies residues of the tautomerase active site indicated in forming substrate 
contact (112). 
 
 
For functional studies of the parasitic MIF orthologs, a native protein 
sequence was considered important because modification of the N-
terminal proline inhibits tautomerase activity (133), and the C-terminus is 
known to mediate subunit oligomerization in the human MIF protein 
(101).  
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4.3 Purification and Characterization of LmMIF 
Recombinant, wild-type sequence LmMIF protein was purified by 
sequential FPLC chromatography in three steps. First, the protein was 
loaded onto a Q-Sepharose column and eluted with a gradient with 
increasing salt concentration between 120 and 180 mM NaCl. Protein-
containing fractions were pooled, rebuffered and reloaded on the Q-
Sepharose column for the second purification step. LmMIF eluted in a pH-
gradient at about pH 6. Final purity was obtained from gel chroma-
tography over a Superdex 75 column (Figure 15).  
 
                              
Figure 15. Sequential purification of LmMIF by anion exchange and size 
exclusion chromatography (A) The protein was stepwise purified starting with a salt 
gradient followed by a pH-gradient over a Q-sepharose column. Final purity was achieved 
by size exclusion chromatography over a S75 column. (B) Purity of LmMIF compared to 
human MIF.  
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As estimated from the SDS-PAGE (Figure 16), the final purity of the 
LmMIF product was >98% and yielded 15 mg of protein per liter of E. coli 
culture. 
The major peak of LmMIF eluted at an apparent molecular mass of 32 
kDa on a size exclusion column (Figure 16). The observed mass of ~32 kDa 
is well above the dimer mass of 24.762 kDa, supporting a trimeric state in 
solution, but the mass is also significantly below the full trimer mass of 
37.143 kDa (106, 108). However, the unusual small partial specific volume 
reported for human MIF strongly supports a trimeric state (108). 
 
 
 
Figure 16. Recombinant LmMIF elutes as a trimer in size exclusion 
chromatography. thyroglobulin (670 kDa), bovine gamma-globulin (158 kDa), chicken 
ovalbumin (44 kDa), equine myoglobin (17 kDa), and vitamin B12  (1.35) were used as 
standards. 
 
 
Electrospray ionization of purified LmMIF protein gave an m/z of 
12383.56 (Figure 17), which is within 0.02% of the predicted mass of the 
translated amino acid sequence (calculated MW: 12381.22 Da) with a 
correct processing of the initiating methionine.  
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Figure 17. Electrospray ionization mass spectrometry of LmMIF showing a 
molecular mass (m/z) that lies within 0.02% accuracy of the predicted m/z (12381.22 Da). 
 
 
4.3.1 LmMIF Activity Studies 
In order to investigate the idea that LmMIF mimics or interferes with 
human MIF function, it was important to determine whether the 
enzymatic activities are conserved in the ortholog by comparing the 
tautomerase activity of pure, recombinant LmMIF with human MIF. 
As shown in Figure 18, LmMIF tautomerizes D-dopachrome, but the 
specific activity for the reaction is 13-fold lower than that measured for 
human MIF (LmMIF: 0.25 mM/min/µM, human MIF: 3.35 mM/min/µM). 
To further study the grade of conservation of the active site, the ability of 
MIF inhibitors to interact with the Leishmania protein was investigated. 
The tested inhibitors included (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-
isoxazole acetic acid methyl ester (ISO-1) and 4-iodo-6-phenylpyrimidine 
(4-IPP). The competitive inhibitor ISO-1 inhibits human MIF but not 
LmMIF, suggesting a selective interaction of this compound with the 
human MIF tautomerization site. In contrast, 4-IPP, which forms a 
covalent modification of the human MIF N-terminal proline (Section 4.1 
above), inhibits the tautomerization activity of both MIF proteins with a 
greater inhibitory effect on LmMIF. 
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Figure 18. Tautomerization activity of LmMIF and human MIF measured with 
the substrate D-dopachrome. A representative reaction is shown for LmMIF at 1 µM 
and for human MIF at 0.1 µM. The small-molecule inhibitors ISO-1 or 4-IPP were 
preincubated with MIF at 1000- or 1-fold molar excess, respectively. The lower 
tautomerase activity of LmMIF made it necessary to use a higher concentration of this 
protein for the inhibition studies. Data are means ± SD of triplicate measurements. The p 
values were calculated by Student’s t test. p < 0.001 for human MIF vs LmMIF, for 4-IPP 
treated LmMIF vs untreated LmMIF, for ISO-1- or 4-IPP-treated human MIF vs 
untreated human MIF, and for 4-IPP-treated LmMIF vs 4-IPP-treated human MIF. 
 
 
4.3.2 Crystallization of LmMIF 
Crystallization conditions for LmMIF were screened by the hanging drop 
vapor diffusion method; crystals grew in several conditions. However, the 
best hit was found for condition 41 of the Crystal Screen (Hampton 
Research). The solution included 0.1 M HEPES-Na (pH 7.5), 20% (v/v) 
isopropanol and 20% (w/v) polyethylene glycol 4000. The rhombohedral 
crystals were prepared reproducibly by mixing 1 µl of protein solution (8 
mg/ml) and 1 µl reservoir solution and appeared after 3 weeks with size 
dimensions of approximately 600 x 500 μm (Figure 19). Selenomethionine 
(Se-Met) LmMIF crystals did not grow under this condition, instead the 
crystals grew after two days using 0.1 M tri-sodium citrate dihydrate (pH 
5.6), 10% (v/v) isopropanol and 20% (w/v) polyethylene glycol 4000 as 
precipitant solution. 
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Figure 19. Crystal of native LmMIF.  
 
 
 
A native and a seleneomethionine substituted crystal obtained under 
these conditions were used to collect diffraction data leading to structure 
determination at beamline X29A in the Brookhaven National Laboratory 
(BNL) (Figure 20). Crystallographic data collection and refinement 
statistics are listed in Table 4. 
 
 
 
Figure 20. Diffraction pattern of native LmMIF. The crystal diffracted to 1.03 Å 
resolution and belonged to the space group R3. 
 
 
 
 
Results 
67 
 
Table 4. Data Collection and refinment statsistics of LmMIF. 
 Native Se-Met 
Data collection     
Space group R3 R3 
Cell dimensions     
    a, b, c (Å) 52.32, 52.32, 96.82 52.11, 52.11, 96.83 
    α, β, γ () 90, 90, 120 90, 90, 120 
  Peak Inflection Remote 
Wavelength (Å) 0.95 0.97912 0.97928  0.96389 
Resolution (Å)* 50-1.03 (1.07-1.03) 1.6 1.6 1.6 
Rsym or Rmerge 0.051 (0.228) 0.066 0.051 0.052 
I / σI 22 (6.8) 6.4 6.8 6.6 
Completeness (%) 95.5 (71.6) 99.7 99.6 99.7 
Redundancy 5.2 (3.4) 7.2 7.2 7.3 
     
Refinement     
Resolution (Å) 10-1.03    
No. reflections 44388    
Rwork / Rfree 0.139/ 0.157    
No. atoms 1004    
    Protein 880    
    Ligand/ion 4    
    Water 120    
B-factors     
    Protein 14.2    
    Ligand/ion 40    
    Water 28.7    
R.m.s deviations     
    Bond lengths (Å) 0.016    
    Bond angles () 2.1    
Ramachandran plot (%)**     
    most favored 94.7    
    allowed   5.4    
*Highest resolution shell is shown in parenthesis.  
**As defined in PROCHECK 
 
 
 
 
4.3.3 The Three-Dimensional Crystal Structure of LmMIF 
The X-ray crystal structure of LmMIF was solved at a resolution of 1.03 Å 
in spacegroup R3. There is 1 protomer with approximate dimensions of 
45*19*18 Å per asymmetric unit that forms a trimer with two protomers 
from adjacent asymmetric units (Figure 21A). As expected, the topology of 
the LmMIF protomer is very similar to human MIF. As its mammalian 
countertype, the protozoan protein consists out of 2 alpha-helixes and 6 
beta-strands of which four form a β-sheet and the remaining two help to 
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stabilize the trimer. The two proteins superimpose very well with a root 
mean square deviation of the Cα backbone of 1.8 Ǻ (Figure 21B). 
 
 
 
C. 
 
Figure 21. Conserved structure between LmMIF and MIF.      
(A). Schematic representation of the LmMIF and human MIF protomers (upper panel) 
and trimers (lower panel) with secondary structure elements shown in blue (β-sheet), red 
(α-helix ) and cyan (random coil). (B). Superimposition of the backbone ribbon diagrams 
of monomeric and trimeric LmMIF (red) and human MIF (green). In the trimeric 
representation, one of the protomers is displayed as backbone trace. Also shown in the 
trimer representation are the sidechain residues implicated in substrate recognition. The 
substrate p-hydroxyphenylpyruvate is displayed in yellow. (C) Sequence alignment with 
secondary structure elements for LmMIF and hMIF. The program Molscript (136) was 
used to prepare Fig. A, PyMOL (104) was used to prepare Fig B. 
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The tautomerase active site is structurally conserved, forming a deep 
pocket around Pro1. The 13-fold lower tautomerase activity of LmMIF 
compared to human MIF (described in 4.3.1) may be explained by 
comparing the tautomerization site of the two proteins. In contrast to 
human MIF, the tautomerase active site of LmMIF shows a negative 
electrostatic potential which is caused by the proximity of Glu65 on the 
base inside the catalytic pocket (Figure 22A). The low tautomerase activity 
can further be explained using a theoretical model of substrate docked in 
the active site of LmMIF (Figure 22B). LmMIF shares with human and 
mouse MIF two out of the five amino acids (Pro1 and Lys35) that have 
been implicated in substrate contact, however three residues are absent. 
The replacement of Ile67 by a Leu in LmMIF is probably less significant 
because the contact involves a backbone hydrogen bond, whereas the 
substitution of Tyr98 and Asn100 by the hydrophobic residues Phe and 
Leu, respectively, eliminates two side chain hydrogen bonds to the 
substrate. While tautomerase activity is reduced in LmMIF, it is notable 
that the overall structure of the N-terminal region and hydrophic pocket 
remain similar as they are conserved in all other MIF or D-dopachrome 
tautomerases that have been characterized.     
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Figure 22. Active site comparison of LmMIF and human MIF. 
(A). Electrostatic surface potential of the tautomerase site of LmMIF and human MIF. 
The negatively charged surface potential is colored in red and the positive potential in 
blue. (B) Molecular model of active site residues implicated in substrate contact for 
LmMIF based on a crystal structure of MIF complexed with p-hydroxyphenylpyruvate 
(112). Residue numbering refers to sequence alignment of Figure 22. The program Spock 
(137) was used to generate Fig. A, PyMOL (104) was used to prepare Fig B. 
 
 
4.3.4 Human and Leishmania MIF Interaction Studies 
Analyzing the crystal structure of LmMIF and comparing to human MIF 
lead to the hypothesis that the parasitic MIF protein might interfere with 
human MIF function by forming mixed oligomers with the later protein. 
This speculation resulted from the overlay of the trimer of human MIF 
and LmMIF; it was evident that a human MIF protomer can theoretically 
be replaced with a LmMIF molecule without causing any clashes in the 
mixed trimer (Figure 23A). This observation was supported by a 
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computational docking program in which one PDB-file with the 
coordinates of a LmMIF dimer and one PDB-file with the coordinates of a 
human MIF monomer were submitted to the ClusProServer. ClusPro 
Server uses ZDOCKs fast Fourier transform to search all possible binding 
modes for the proteins, evaluating based on shape complementarily, 
desolation energy, and electrostatics. The human MIF protein was docked 
in correct orientation to form a complete trimeric molecule (Figure 23B). 
To examine this possible interaction, yeast-two-hybrid studies were 
performed. 
 
 
Figure 23. Theoretical mixed trimer formation of human and Leishmania MIF. 
(A) One monomer of human MIF (Connolly surface, colored by CPK) is replaced with a 
LmMIF ortholog (stick representation). (B) Docking of human MIF (blue) into 2 molecules 
of  LmMIF (green) performed by using ClusPro Server. Figures were prepared by using 
PyMOL (104). 
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4.3.4.1 Yeast Two Hybrid 
In a recent study a yeast two hybrid system where the MIF cDNA served 
as “bait” and a human pituitary cDNA library was used as “prey’; several 
positive colonies encoded the MIF cDNA in the prey-vector (138) showing 
the oligomer formation of MIF can be observed in this system. Thus, a 
similar approach was used to identify whether human MIF can interact 
directly with LmMIF.  
In the Matchmaker GAL4 Two-Hybrid system used for the present study, 
a bait gene was expressed as a fusion of the GAL4 DNA-binding domain 
(DNA-BD) and the prey gene was expressed as a fusion of the GAL4 
activation domain (DNA-AD). When the DNA-binding and the DNA-
activation domain are brought in proximity by interaction of the bait and 
prey proteins, the transcription of four reporter genes is activated.  
Human and Leishmania MIF were cloned in both the bait or prey vector 
allowing four possible combinations of co-transformation into the AH109 
cell line: 
 hMIF-BD and hMIF-AD 
 LmMIF-BD and LmMIF-AD 
 hMIF-BD and LmMIF-AD 
 LmMIF-BD and hMIF-AD 
The co-transformation of the hMIF/hMIF or LmMIF/LmMIF bait-prey pair 
served as positive control, respectively.  
While the positive yeast controls expressing hMIF/hMIF or 
LmMIF/LmMIF grew on medium- (SD/-His/-Leu/-Trp) and high- (SD/-
Ade/-His/-Leu/-Trp/X-α-gal) stringency selection plates, the mixed trans-
formations did not (Figure 24). The results indicate that a potential inter-
ference of LmMIF with the human immune system is not mediated by 
mixed trimer formation and disruption of the host MIF cytokine function.  
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Figure 24. No mixed trimer formation of human and Leishmania MIF as 
assayed by a yeast two hybrid system. Bait and prey vector were co-transformed as 
indicated and spread on high-stringency selection plates (SD/-Ade/-His/-Leu/-Trp/X-α-
gal). Interaction of proteins was analyzed 3 days later.  
 
 
4.3.5 In vitro Binding of LmMIF to the Human MIF Receptor 
CD74 and to the Human MIF-tethering Protein p115 
 
4.3.5.1 The MIF-CD74 Interaction 
The cytokine MIF was shown to activate cells by engaging its cell surface 
binding receptor, CD74, and a high-affinity binding interaction between 
MIF and the CD74 ectodomain (CD7473-232, sCD74) has been demonstrated 
(55). 
To examine the binding of LmMIF to the human MIF receptor, a 
competition-binding assay was utilized to test whether recombinant 
LmMIF competes with biotinylated human MIF for binding to 
immobilized sCD74 (Figure 25A). LmMIF inhibited the interaction 
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between human MIF and sCD74, but inhibition was not as complete as 
achieved with human MIF as a competitor.  
The results of the competition assay were confirmed by measuring the 
equilibrium dissociation constant for the binding of LmMIF to sCD74 by 
surface plasmon resonance spectroscopy (BIAcore analysis). The real-time 
binding interactions measured by this method revealed a high affinity of 
LmMIF to the human MIF receptor CD74 with a Kd of 2.9 x 10-8 M (Figure 
25B). This contrasts with the previously determined Kd of 9.0 x 10-9 M for 
the binding of human MIF to sCD74 (55). These results indicate that 
LmMIF binds to the human MIF receptor with high affinity, albeit with a 
3-fold lower Kd than recombinant human MIF. 
 
 
Figure 25. LmMIF binds to the MIF receptor CD74. (A) Concentration dependent 
binding of LmMIF and human MIF to the immobilized, human MIF receptor CD74 
ectodomain (sCD74) using biotinylated human MIF as a competitor. A neutralizing anti-
MIF receptor mAb (LN2) and heat-denatured, recombinant human MIF served as 
positive and negative controls for this assay. Values are the means of quadruplicate 
measurements. (B) Realtime surface plasmon resonance analysis (BIAcore) of the 
interaction between recombinant LmMIF and sCD74. 
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4.3.5.2 The LmMIF-p115 Interaction 
In a recent study on the secretion of the leaderless cytokine MIF, the 
Golgi-associated protein p115 was identified as an intracellular binding 
partner and critical component for the regulated secretion of MIF from 
monocytes/macrophages (138). As macrophages are the primary hosts of 
the Leishmania parasite it was of interest to elucidate whether p115 
interacts with LmMIF and possibly uses the host’s secretion pathway to 
release LmMIF from infected cells for immune evasion strategies.  
In order to biochemically analyze the interaction between LmMIF and 
p115, the carboxy-terminal region of p115 (p115702-962) described to 
interact with human MIF was expressed and purified from E.coli as a 
histidine-tag fusion protein (Figure 26).  
 
 
Figure 26. SDS-PAGE of p115702-962. Following cell disruption the soluble proteins were 
loaded onto a Ni-NTA column. In the second purification step (Superdex S75), all 
impurities contained in the Ni-NTA pool were eliminated.   
 
 
Utilizing the competition binding assay, an inhibition of the interaction of 
biotinylated hMIF with p115702-962 was observed with increasing 
concentrations of LmMIF (Figure 27). 
Moreover, the competition of LmMIF for p115702-962 binding is significantly 
stronger than the binding observed for hMIF with the strongest difference 
at low protein concentration (0.25 – 1µM). This finding is in contrast to the 
binding of LmMIF to the human MIF receptor CD74 where a stronger 
binding of the mammalian protein to the receptor was detected (Figure 25). 
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The binding of LmMIF to p115702-962 suggests the possible secretion of the 
parasitic protein from infected cells is mediated by the same pathway than 
proposed for the host protein.  
 
 
  
Figure 27. LmMIF binds to p115702-962. Concentration dependent binding of LmMIF 
and human MIF to the immobilized carboxy-terminal region of p115702-962 using 
biotinylated human MIF as a competitor. Lysozyme served as negative control for this 
assay. Values are the means of triplicate measurements. 
 
 
4.3.6 Cellular Uptake of LmMIF 
Although MIF is a cytokine and thus modulates immune activity by 
receptor-mediated pathways intracellular actions by direct interaction 
with the Jun activating binding protein (Jab1) (139), p53 (132) and p115  
(138) have been described. These studies suggest that cytokine activities of 
MIF are mediated by p53 and Jab1-dependent pathways after uptake into 
target cells. The amino acid residues 57-63 of human MIF, which include 
the CXXC motif are important for Jab1 binding and modulation. This 
motif is absent in LmMIF. Similarly, Cys83, critical for p53 interaction is 
absent in the ortholog. In light of these studies, it was of interest to 
address whether LmMIF is internalized into target cells giving the 
potential of modulating intracellular pathways of non-infected cells. 
Figure 28 shows, exogenous, fluorescein-labeled, recombinant LmMIF 
(and human MIF) enters the macrophage cell line RAW264.7 and is 
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targeted into the cytosolic compartment with no observed difference 
relative to human MIF. 
 
 
Figure 28. LmMIF is internalized by macrophages.  
Exogenously added LmMIF is internalized by RAW 264.7 macrophages. 1.5 μM 
fluorescein-labelled LmMIF or human MIF (green) was added to the cells and staining for 
β-actin (red) was performed 30 min later as described in Materials and Methods. 
 
 
4.3.7 Chemotaxis Activity of LmMIF for Human Monocytes 
A major target of human MIF is the macrophage, a key cell in immune 
and inflammatory response. Once produced, MIF inhibits their movement 
(42, 49), however, MIF also exerts a chemoattractant effect on 
mononuclear cells. Given the fact that macrophages are the final host of 
the Leishmania parasite, a crucial step for establishment of disease may 
be the attraction and accumulation of their target cells. As shown in 
Figure 29, human peripheral blood monocytes migrated to a concentration 
gradient of LPS-free recombinant LmMIF and human MIF across a 
transwell membrane. These results demonstrate that LmMIF can 
chemotactically mobilize macrophages in a manner quantitatively similar 
to human MIF. As with the tautomerase assay, the small molecule MIF 
antagonist, ISO-1, binds to the human MIF tautomerization site (118) and 
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inhibits MIF-induced chemoattraction (140) whereas LmMIF function is 
not influenced by the small molecular inhibitor. In contrast, the covalent 
inhibitor, 4-IPP, inhibited migration induced by MIF and LmMIF. 
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Figure 29. LmMIF induces mononuclear cell migration.  
Human peripheral blood mononuclear cells (PBMCs) were subject to migration analysis 
with or without 8.1 nM (100 ng/ml) recombinant LmMIF in the lower chamber. Human 
MIF served as positive control. The MIF inhibitor ISO-1 was added in 10, 100 and 1000 
fold-molar excess to the recombinant protein, and the inhibitor 4-IPP was added in 10 
fold-molar excess. Results are representative of two independent experiments and are 
expressed as the mean number of 12 counted fields ±SEM. The p values were calculated 
by the Student’s t test. **p<0.01, ***p<0.001 for LmMIF or human MIF versus protein 
with inhibitors. 
 
 
4.4 Purification and Characterization of PfMIF 
Plasmodium falciparum MIF (PfMIF) was purified by sequential anion 
exchange chromatography comparable to the methodology employed for 
LmMIF purification. The protein lysate first was loaded on a Q-Sepharose 
column equilibrated with Tris (pH 8.0), 10 mM NaCl, 20 mM (Buffer A) 
and eluted with a pH-gradient from pH 8 towards pH 6.3. The protein 
containing fractions were pooled, re-buffered (Buffer A) and re-loaded on 
the Q-Sepharose column equilibrated with Buffer A and eluted via salt 
gradient. Final impurities were eliminated by size exclusion 
chromatography over a Superdex S75 column equilibrated with PBS. The 
final product is shown in Figure 30 with an estimated purity of >98%. 
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Similar to LmMIF, PfMIF elutes in a S75 size exclusion column at an 
approximate molecular mass of 32 KDa which is consistent with a dimer 
or trimer of the 12.713 KDa protein (Figure 30). 
 
 
 
 
 
Figure 30. Purified recombinant PfMIF. (A) Purity of PfMIF compared to human 
MIF is analyzed by SDS-PAGE followed by Coomassie staining. (B) PfMIF elutes at an 
apparent molecular weight of 32 kDa in size exclusion chromatography (blue). Standards 
(red) included thyroglobulin (670 kDa), bovine gamma-globulin (158 kDa), chicken 
ovalbumin (44 kDa), equine myoglobin (17 kDa), and vitamin B12 (1.35kDa).  
 
 
Figure 31A displays the grade of conserved residues of PfMIF in a three-
dimensional model based on the sequence alignment from 4.2.1. The 
residues surrounding the tautomerase active site are highly conserved, 
however, no tautomerase activity of PfMIF was observed when tested with 
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the substrate D-Dopachrome (data not shown). An enzymatic activity was 
observed using the substrate HPP (Figure 31B), but the measured activity 
at standard assay conditions was more than 100-fold lower compared to 
human MIF.  These findings contrast with the data obtained for LmMIF, 
which showed high enzymatic activity for the substrate D-Dopachrome 
and very little for HPP.    
 
                          A. 
                            
                        B. 
 
Figure 31. The active site of PfMIF is conserved. (A) Three-dimensional model of 
PfMIF based on the sequence similarity of to human MIF displayed on the structure of 
human MIF where dark red shows identical residues and white shows no similarity. HPP 
is displayed in the active site. This figure was prepared with Pymol (104) and ProtSkin 
(141).  (B) Tautomerase activity of PfMIF with the substrate p-hydroxyphenylpyruvate.  
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4.4.1 In vitro Binding of PfMIF to the human MIF Receptor 
CD74 
Real-time surface plasmon resonance analysis (BIAcore) revealed PfMIF 
to bind the human MIF receptor CD74 with a similar binding constant as 
measured for LmMIF (Kd = 2.67 x 10-8 M) but ~3 fold lower than human 
MIF itself.    
 
 
 
Figure 32. PfMIF binds to the MIF receptor CD74. Real-time surface plasmon reso-
nance analysis (BIAcore) of the interaction between recombinant LmMIF and sCD74. 
 
 
4.4.2 Crystallization of PfMIF 
Prior to screening for crystallization conditions, PfMIF was concentrated 
to 11 mg/ml. The best crystallization hit was obtained from condition 17 of 
the Hampton Crystal Screen (0.1 M Tris (pH 8.5), 2 M LiSO4, 30% PEG 
4000). This condition was optimized in a 24-well plate format by 
performing a pH gradient from pH 7.5 to pH 9.0 and a precipitant 
gradient from 25% to 35% PEG 4000. Several crystals grew over 5 – 8 
days. However, these crystals had an irregular shape which could not be 
improved by additives. Nevertheless, X-ray diffraction data were collected 
on an R-axis IV detector (Rigaku) at the macromolecular crystallography 
facility at the Yale University School of Medicine. The crystal diffracted to 
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3.1 Å in spacegroup I222. However, molecular replacement against human 
MIF using the collect dataset was not successful.   
 
Figure 33. Diffraction pattern of PfMIF 
 
 
It is attempted to further optimize the initially successful crystallization 
condition, and to produce Se-Met derivates for solving the structure of 
PfMIF by multiwavelength anomalous diffraction (MAD) phasing.  
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4.5  Mapping the Binding of MIF to the Chemokine 
Receptor CXCR4 
MIF acts as a major regulator of inflammatory cell recruitment and 
atherogenesis. A recent study describes these chemokine-like functions of 
MIF to be mediated by interaction with the chemokine receptors CXCR4 
and CXCR2. Moreover, MIF was shown to compete with CXCL12 for 
binding of the CXCR4 receptor (56). However, the molecular details of this 
interaction have not yet been determined.   
To investigate whether the N-terminal region of CXCR4, which is the 
determinant for the binding of CXCL12 (142) is also involved in binding to 
MIF, cell-transmigration studies were performed. As shown in Figure 34A, 
human and LmMIF-induced chemoattraction of PBMCs is efficiently 
blocked by the addition of CXCR41-27. In order to analyze whether the 
inhibitory effect observed in cell-transmigration is caused by direct 
binding of MIF to CXCR41-27, protein-protein interactions were probed by 
steady state fluorescence spectroscopy. LmMIF showed significant 
increase in fluorescence intensity in a CXCR41-27 concentration-dependent-
manner with a high affinity interaction (Kd = 3.1±0.8 μM) (Figure 34B). 
The measured dissociation constant is in range with the previously 
reported Kd of 1.3±0.5 μM for the interaction between CXCL12 and 
CXCR41-38 as determined by NMR-spectroscopy (143). Similar results were 
obtained for human MIF, however, due to low intrinsic fluorescence the Kd 
was not calculated. The direct interaction between the N-terminal tail of 
CXCR4 was also confirmed by the competitive binding assay with the 
peptide bound to the surface and competition of biotinylated MIF with 
increasing concentration of human MIF (Figure 34C). 
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                        A. 
 
                                          
                          B. 
 
                         C. 
                         
Figure 34. CXCR41-27 efficiently blocks MIF induced mononuclear cell migration 
by direct interaction. (A) Human PBMCs were subjected to migration analysis in the 
presence of human MIF or LmMIF. CXCR41-27 was added in 10-fold molar excess. Results 
are expressed as mean±S.D (n = 12). (B) Binding of CXCR41-27 to LmMIF observed by 
steady-state tryptophan fluorescence spectroscopy reveals an apparent dissociation 
constant of 3.1 (±0.8) µM. (C) Competition binding assay. 
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To map the MIF binding site for CXCR4, initial NMR studies were 
performed. 15N-MIF in the presence or absence of CXCR41-27 was subjected 
to NMR spectroscopy. The resulting 1H15N-HSQC spectra indicate 
differences between human MIF and the complex between human MIF 
and CXCR41-27 (Figure 35A). Individual residues that might be involved in 
the interaction are indicated in Figure 35B. 
 
 
Figure 35. NMR spectroscopic studies of human MIF and CXCR41-27 interaction. 
(A) Overlay of 15N-1H-HSQC spectra of 300 μM 15N-hMIF (blue) and 300 μM 15N-hMIF 
with 900 μM CXCR41-27 peptide (red). Spectra were collected at 25˚C at pH 6.8. 
Resonance peaks with the largest chemical shift changes are indicated for the human 
MIF 15N-1H-HSQC spectra. (B) Trimer of human MIF with residues undergoing the 
greatest chemical shift changes upon peptide binding (red spheres). (C) Surface rendering 
of the trimer of human MIF. Greater chemical shift changes upon peptide binding are 
displayed in increasing intensity of red. Each subunit is colored in a different shade of 
blue. 
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5 Discussion 
5.1 The Prototypic Covalent MIF Inhibitor 4-IPP 
The cytokine macrophage migration inhibitory is an important regulator 
of the innate and adaptive immunity and plays a pivotal role in the 
pathogenesis of chronic and acute inflammatory diseases such as septic 
shock (47), cancer (73), and rheumatoid arthritis (70). Serum MIF levels 
positively correlate with the severity of Gram-negative and -positive sepsis 
in humans (144). MIF levels are also markedly elevated in most tumor 
types (73) and correlate with rheumatoid arthritis severity (145). 
Several biological treatment options such as anti-MIF antibodies or 
soluble receptors might be an option to counteract MIF related diseases. 
In fact, studies investigating neutralizing antibodies have proven the 
potential of targeting MIF as a treatment option for inflammatory disease 
(68, 146, 147). Although biological antagonists, such as etanercept and 
infliximab are successfully used as anti TNF-α therapies in treatment of 
rheumatoid arthritis (148), the production of such biological agents is 
difficult, time consuming and expensive; the dose necessary for an 
effective anti-MIF treatment would cause high costs and thus a 
development of medication from this direction seems unlikely. A much 
more affordable option is the use of non-protein based inhibitors. While in 
general the identification or design of small molecule cytokine inhibitors is 
problematic due to the complex interactions between cytokines and their 
receptors, MIF’s unique enzymatic activity allows for fast screening of 
potential inhibitors.  
Existing inhibitors have been shown to suppress MIF’s cytokine function 
and promising effects on MIF related diseases have been described in 
mouse models investigating septic shock (54, 120) and West Nile virus 
infection (149). These positive effects are even more impressive when 
considering the relatively low affinity of the existing MIF inhibitors for 
MIF’s D-dopachrome tautomerase active site (micromolar range); this 
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supports the potential therapeutic benefits for an inhibitor with even 
higher binding affinity. 
The co-crystal structure of the MIF◦4-IPP-complex shows that 4-IPP is de-
halogenated upon contact with enzymatically active MIF and 
subsequently forms a covalent bond between position 4 of the pyrimidine 
and the N-terminal nitrogen of proline 1. This inhibitor not only has a 
~10-fold higher potency in blocking the catalytic reaction of MIF, but the 
covalent modification also makes this inhibitor to a suicide substrate for 
MIF. Electrophilic compounds that produce covalent modification are 
generally of negligible interest for pharmaceutical development due to the 
potential for side effects, such as  non-specific irreversible modification of 
non-targeted proteins and the formation of neo-antigens. Nevertheless, 
such compounds may be a viable option for terminal conditions such as 
metastatic cancer. Non-covalent inhibitors provided proof-of-concept for 
the therapeutic utility of blocking MIF (54, 118, 120). However, for these 
non-covalent inhibitors the homotrimeric structure of MIF and the 
assembly of the hydrophobic pocket are required for binding; as soon as 
the trimer dissociates, the inhibitory effect is lost. This is of particular 
interest because the oligomeric state of MIF in physiological conditions is 
still debated in the MIF community (106, 108). Whether the trimeric form 
of MIF alone is responsible for MIF’s biological functions or if the dimeric 
or monomeric forms also contribute to certain biologic functions remains 
under active investigation. Once bound, a covalent inhibitor has the 
potential to overcome the limitations of blocking only the trimeric form of 
MIF.  
Based on the MIF◦4-IPP crystal structure, our collaborators Mitchell and 
colleagues were able to identify four analogues of 4-IPP that are ~10 – 20x 
more potent than parental 4-IPP in blocking MIF-dependent catalysis 
(IC50 ~200 – 400 nM). Of note, the group has investigated a potential 
toxicity of 4-IPP in a mouse model by intraperitoneal injections of 1 – 4 mg 
daily over a course of 7 days and observed no acute toxicity. 
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5.2 The MIF Ortholog from Leishmania major 
Leishmaniasis is a vector-borne parasitic disease that is transmitted 
during the bloodmeal of an infected sandfly. Depending on the Leishmania 
species and the host's immune response, the disease presents a spectrum 
from self-healing cutaneous lesions to severe visceral disease and death. 
The early inflammatory response is suggested to be critical for the 
outcome of the Leishmania infection. It was demonstrated that the local 
control of infection and the development of subsequent immunity is 
mediated by the host’s innate, antimicrobial immune response and by an 
adaptive Th1 cell response (150-152). However, Leishmania parasites 
have acquired highly sophisticated immune evasion mechanisms to escape 
the host’s immune response. Some of the known strategies include a 
“silent entry” in host phagocytes by receptor-mediated-phagocytosis, thus 
avoiding the initial activation and the oxidative burst of the infected 
macrophages (153, 154), the inhibition of host defense mechanisms such as 
protein kinase C (PKC) activation (155) and upregulation of iNOS (156); 
and most importantly, the inhibition of the initial IL-12 production of 
infected macrophages, thus preventing T-cell priming towards a Th1 
response (157). The exact mechanisms by which Leishmania spp. 
influences the host’s immune response nevertheless remain poorly 
understood and the mediators regulating the immune evasion of the 
parasite are just beginning to emerge. 
Host MIF was previously shown to play a critical role in mediating the 
hosts’ resistance to Leishmania infections. Purified, recombinant MIF was 
reported to activate murine macrophages to kill L. major more efficiently 
(98). Correspondingly, MIF deficient mice were described as more 
susceptible to L. major infections (99). In addition, a recent clinical study 
reported an increased MIF level in CD2+ T-cells of L. donovani infected 
patients after anti-leishmanicidal treatment (158).  
The recent discovery of two MIF orthologs in the L. major genome has 
raised the question of whether these protein products influence the host’s 
immune system. This hypothesis is supported by the finding of MIF-
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orthologs in several primitive eukaryotic parasites (Brugia malayi (87), 
Ancylostoma ceylanicum (88), Eimeria spp. (159) Trichinella spp (160), 
Plasmodium spp. (89, 90)) that show remarkable similarity to the 
mammalian counterpart. 
In my thesis, a potential mediator of immune evasion mechanisms from 
Leishmania major, the human MIF ortholog Lm1740MIF (LmMIF) has 
been characterized and the results clearly support its hypothesized role in 
immune evasion strategies. 
Recombinant LmMIF was produced from a high yield bacterial expression 
system and purified by fast protein liquid chromatography, resulting in a 
pure product with negligible concentrations of endotoxin for functional 
studies. Native LmMIF was cloned in a native sequence and not fusion 
protein form because of evidence that modifications of both the C- and N- 
terminus of the protein interfere with the correct fold and function of the 
protein (101, 113). 
The solution of the high resolution x-ray crystal structure of LmMIF 
revealed the primary structure identity of 21% between LmMIF and 
human MIF is extended to the three-dimensional-fold of the two proteins 
(RMSD =1.8 Å). In particular, the hydrophobic pocket of the tautomerase/ 
isomerase active site displays a remarkable conservation and not 
surprisingly, allows the parasitic protein to catalyze the tautomerization 
reaction of the non-physiological substrate D-Dopachrome. However, a 
difference in the electrostatic potential due to the presence of Glu65 and 
three additional significant amino acid substitutions of residues that have 
been implicated in forming substrate contacts (112) distinguish the active 
sites sufficiently to be selective for different small molecules. While all 
parasitic MIF orthologs that have been studied to date have been shown to 
posses at least some tautomerase or isomerase activity for one of the 
substrates D-dopachrome or HPP (86-90), no inhibitor for an active site of 
parasitic MIF proteins has been reported previously. Herein, the human 
MIF inhibitor 4-IPP is revealed to interfere with the tautomerase activity 
of LmMIF and moreover, was shown to efficiently block the LmMIF-
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induced chemotaxis of monocytes whereas the reversible MIF inhibitor 
ISO-1 did not influence LmMIFs function. Small molecule inhibitors of 
human MIF that are designed to bind the tautomerase site and interfere 
with biological function are presently in preclinical development. Given 
the structural and functional differences in the tautomerase sites of 
human and Leishmania MIF, it is possible that inhibitors may be designed 
to interfere selectively with Leishmania MIF. 
MIF has been shown previously to bind to the CD74 extracellular domain 
on macrophages, thus activating the ERK1/2 MAP-kinase signaling 
pathway (55) and induction of cell survival (60). LmMIF bound with high 
affinity to the extracellular domain of the human MIF receptor CD74, as 
assessed both by an in vitro competition binding assay and by surface 
plasmon resonance spectroscopy. Although the residues involved in 
forming surface contacts between MIF and the extracellular domain of the 
MIF receptor CD74 are not known, MIF’s N-terminal region appears to 
play an important role in these interactions (119). The structural 
homology between Leishmania MIF and human MIF is sufficiently 
conserved to allow for high affinity binding of LmMIF with the human 
receptor.  
In addition to the described functional activity of LmMIF to attract 
monocytes, it is important to mention that Daniela Kamir was able to 
show that recombinant  LmMIF protects macrophages from apoptosis and 
activates ERK1/2 signal transduction in a CD74- dependent manner (53). 
Consistent with the 3-fold lower Kd of LmMIF for the CD74 receptor, the 
activity in these functional assays was in general reduced compared to 
mammalian MIF. 
The present results indicate that the Leishmania ortholog of the cytokine 
MIF activates the human MIF receptor CD74 to influence the functional 
responses of monocytes/macrophages. Because Leishmania is an 
intracellular parasite of the monocyte/macrophage, it may be hypothesized 
that one function of Leishmania-encoded MIF is to sustain monocyte/ 
macrophage survival and contribute to the persistence of the parasite so 
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that it may complete its infectious life cycle. The precise molecular 
mechanism underlying LmMIF’s activation of CD74 remains to be 
investigated; for instance, the protein may be secreted from infected cells 
(161) and bind to the cell surface receptor CD74, or it may engage CD74 
intracellularly.  
Of note, a recent study examining the unconventional secretion of MIF 
revealed p115 as an intracellular binding partner and critical component 
for the regulated secretion of MIF from monocytes/macrophages (138). A 
competition binding assay performed in the present work suggests that 
LmMIF binds the Golgi-associated protein p115 with high affinity and 
more efficiently than human MIF. This finding allows us to hypothesize 
that LmMIF expressed from the L. major amastigote stage in infected 
macrophages makes use of the human MIF secretion pathway to activate 
the CD74-dependent ERK1/2 survival-signaling pathway (60) of the hosts 
cell in an autocrine manner. It is also notable that preliminary 
experiments suggest that LmMIF also actives AKT-signaling (data not 
shown), a survival pathway that was previously reported to enhance cell 
survival by autocrine action of MIF in a CD74-dependent manner (64).  
With Lm1740MIF (LmMIF), this study addressed only one of the two MIF 
orthologs expressed by L. major. The second ortholog Lm1750MIF, which 
has a sequence identity of 21% to the human protein and 58% to 
Lm1740MIF, was shown to protect RAW264.7 macrophages from 
apoptosis. Whether Lm1750MIF also is active in enzymatical and 
functional assays has to be determined and might be essential for a 
successful development of anti-leishmanicidal treatment options based on 
MIF orthologs.      
Although the data obtained are consistent with a role for Leishmania MIF 
in modulating the host immune response, they do not exclude the 
possibility of an intrinsic function for LmMIF in the growth or replication 
of the parasite. A physiological role for LmMIF in the parasite life cycle 
and a closer examination of whether these proteins function as virulence 
factors may be attained by creating strains of Leishmania lacking MIF 
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orthologs. Such studies also may provide support for the selective, 
pharmacological targeting of Leishmania MIF for therapeutic benefit. 
An additional question posed by the findings of this thesis was whether 
there exist further functional roles for Leishmania MIF with respect to 
host-parasite interaction. The chemokine receptors CXCR2 and CXCR4 
have recently been shown to be integral components by which MIF 
triggers leukocyte chemotaxis (56). Studies in regards to the interaction 
between CXCR2/4 and MIF are ongoing, and the inclusion of LmMIF in 
these analyses is crucial to further elucidate the functional mechanisms of 
the parasitic MIF protein. LmMIF also might use the p115-mediated 
secretion pathway to enable it to act as a chemoattractant for the 
recruitment of new host cells (20, 30) via the chemokine receptors CXCR2 
and CXCR4  (56).  
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5.3 Interaction of Human and Leishmania MIF with the 
Chemokine Receptor CXCR4 
Activation of the guanine nucleotide-binding protein (G protein)-coupled 
receptor CXCR4 by its cognate ligand CXCL12 is hypothesized to occur 
through a two site mechanism. According to this model, CXCL12 makes 
the initial contact with the N-terminus of the receptor. Subsequently, the 
chemokine interacts with a secondary site on the receptor, which leads to 
high affinity binding and receptor activation (162) (Figure 36). The N-
terminal 17 residues of CXCR4 were described as the principal 
determinants of binding of CXCL12 to CXCR4, with a major contribution 
from the first six residues (142).   
 
 
Figure 36. Model of the interaction between CXCL12 and its receptor CXCR4. 
The scheme indicates that chemokines interact first with their docking and then with 
their triggering site. The extracellular loops connecting helical segments are omitted in 
the middle and right-hand schemes for clarity (162). 
 
Although the structure of MIF is unique with no significant sequence 
homology to chemokines, it possesses many functional properties of a 
chemokine: MIF induces integrin-dependent arrest and transmigration of 
monocytes and T-cells and competes with the cognate ligand CXCL12 for 
the binding to the chemokine receptor CXCR4 (56). In the present study, 
the molecular mechanism by which MIF interacts with the chemokine 
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receptor CXCR4 was addressed. The four assays used in this study, NMR 
spectroscopy, steady-state fluorescence spectroscopy, competition binding 
assay, and cell transmigration, confirmed independently, that MIF, like 
CXCL12, interacts with the N-terminal 27 residues of CXCR4. Notably, 
the binding affinity (Kd + 3.1±0.8 μM) was similar to the previously 
reported binding constant for the interaction between CXCL12 and 
CXCR41-38 (143). Whether MIF binding occurs in a similar manner as 
described for CXCL12 (in a two step binding process, Figure 36) has not 
been addressed, neither can it be excluded that a different length nor 
posttranslational modifications of the N-terminal peptide, in particular 
sulfation, improves the binding affinity for MIF. The described interaction 
of MIF/LmMIF with CXCR4 not only provides new molecular details and 
insights into MIF-related autoimmune and inflammatory diseases, but 
also unfolds a possible new pathway of parasitic MIF-orthologs to interfere 
with the host immune system. Further study of the molecular mode of 
interaction might provide a new opportunity to block the (parasitic)-
MIF◦CXCR4 interactions specifically and thus may aid in the design of 
new drugs targeting both MIF-related diseases and immune evasive 
strategies of parasites. To accomplish this aim, the co-crystallizations of 
the MIF◦CXCR41-27 complex as well as more extensive NMR studies are 
intended.   
Further studies also should be aimed to elucidate whether active site 
inhibitors of MIF can interfere with the binding of MIF to CXCR2 and 
CXCR4. Addition of the N-terminal CXCR4 peptide in a MIF tautomerase 
activity assay did not result in inhibition of this enzymatic activity (data 
not shown). These results indicate that CXCR41-27 does not bind the 
enzymatically active N-terminus of MIF and thus inhibitors of the active 
site might not influence MIF◦CXCR41-27 binding directly. However, 
monocyte migration assays clearly showed that the tested inhibitors 
abolish MIF induced cell migration. Because CXCR2 and CXCR4 are 
suggested as mediators of MIF’s ability to induce cell migration (56), these 
results suggest that the tested inhibitors block the MIF◦CXCR2/4 
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interaction and/or activation, perhaps by interfering with the binding of 
additional regions of the chemokine receptors that have not been 
addressed in this study. The MIF◦CXCR2 interaction has not been 
investigated in this thesis, the methods used for the examination of the 
MIF◦CXCR41-27 interaction however, can be transferred to assess whether 
the N-terminal region of CXCR2 plays a similarly important role in the 
interaction with MIF. 
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5.4 The MIF Ortholog from Plasmodium falciparum 
The role of host MIF in malaria infection previously has been addressed 
and a correlation between disease development and MIF-level has been 
described (92, 94, 95, 163, 164). Furthermore, the parasitic homolog of 
Plasmodium falciparum (PfMIF) was initially characterized by two groups 
in the year 2007 (89, 90). However, in both studies the PfMIF sequence 
was cloned and expressed with either an amino- (90) or a carboxy- 
terminal tag (89) for affinity purification. As discussed earlier, both the N-
terminus and the C-terminus of MIF are crucial for MIF’s function and 
oligomerization, thus the purification and characterization of the native 
sequence PfMIF is considered critical for a decisive study.  
In accordance to the previously reported elution of histidine-tagged PfMIF 
at a calculated mass of 30 kDa (90), the purified native sequence PfMIF 
protein elutes at ~32 kDa as determined by size exclusion 
chromatography. Based on a report revealing the human MIF-trimer to 
have an unusual small partial specific volume (108) and observations from 
our lab obtained from dynamic light scattering experiments, we conclude 
that PfMIF (like LmMIF) is a trimer in solution. However, further studies 
are required to determine the oligomeric status with certainty at 
physiological concentrations. 
The data obtained in this work concerning the direct interaction of PfMIF 
with the human MIF-receptor CD74 with high affinity match well with 
the previously reported findings of PfMIF’s ability to mimic the function of 
the host’s protein. These results strongly support the presumed role of 
PfMIF in immune evasion mechanisms. To further examine the relevance 
of the Plasmodium MIF protein in the course of disease, it is inevitable to 
carefully investigate the pathogenicity of Plasmodium parasites lacking 
the MIF gene. Although it was reported previously that MIF gene-
deficient P. berghei parasites exhibit no significant change in growth 
characteristics or virulence features during blood stage infection in 
rodents, the number of circulating reticulocytes was reported to be higher 
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in hosts infected with the knockout parasites (90). Recent data also 
indicate that mice infected with MIF-knockout parasites display a marked 
difference in the cytokine expression profile compared to mice infected 
with wild type parasites (personal communication; Tiffany Sun and 
Richard Bucala). 
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6 Summary 
The cytokine macrophage migration inhibitory factor (MIF) is a key 
mediator of the innate and adaptive immune system and plays a critical 
role in many inflammatory diseases. MIF is required to combat serious 
infections; however, high-level production of MIF has been linked to a 
severe outcome of many diseases including adult respiratory distress 
syndrome, septic shock, rheumatoid arthritis, atherosclerosis and cancer. 
Over the last years, MIF has also been ascribed important functions in the 
host defense against several parasitic infections. Consequently, anti-MIF 
therapies have been suggested as a potential therapeutic approach for 
treating MIF-related diseases.  
Unique among cytokines, MIF possesses an enzymatic activity that is 
evolutionarily conserved. Herein, 4-iodo-6-phenylpyrimidine (4-IPP), a 
MIF inhibitor which is ~ 5 – 10 times more potent in blocking MIF-
dependent catalysis than other prototypical MIF inhibitors is described. 
Crystallographic studies reveal 4-IPP to serve as a suicide substrate for 
MIF, resulting in the covalent modification of the catalytically active N-
terminal proline and loss of function of MIF-induced monocyte migration.   
Additionally, two parasitic orthologs of MIF, which are produced by the 
obligate intracellular parasites, Leishmania major (LmMIF) and 
Plasmodium falciparum (PfMIF) were studied. An interest in the 
structure and function of MIF orthologs from parasites has emerged 
recently as they might have relevant functions in corrupting the host 
MIF’s induced immune defense mechanisms. By co-evolving with the 
immune system, parasitic organisms have evolved specialized strategies to 
circumvent the host’s immune defense mechanisms to increase their own 
chances of survival. To assess whether LmMIF and PfMIF have the 
potential to disrupt immunological pathways of the host’s immune system, 
the parasitic proteins were recombinantly produced and purified. LmMIF 
and PfMIF show significant binding interaction with the human MIF 
receptor, CD74 (Kd ~ 2.8 x 10-8 M), and like its mammalian counterpart, 
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the recombinant LmMIF protein is internalized by macrophages, induces 
monocyte cell migration, ERK1/2 MAP kinase activation, inhibits the 
activation-induced apoptosis of macrophages and binds the Golgi-
associated tethering protein p115. The Leishmania MIF protein shows 
significant structural homology with human MIF as revealed by a high-
resolution x-ray crystal structure (1.03 Å). Significant differences between 
the two proteins in the N-terminal tautomerization site are evident, and 
evidence for the selective, species-specific inhibition of MIF by small-
molecule antagonists that target this site is provided. 
Finally, this thesis was aimed to further elucidate the molecular basis of 
MIF’s chemokine-like functions which were recently shown to be mediated 
through interaction to the chemokine receptors CXCR4 and CXCR2. 
However, the molecular details of this interaction have not yet been 
determined. Herein, a peptide derived from the N-terminal extracellular 
region of the CXCR4 receptor as a site of interaction with human MIF and 
Leishmania major MIF is described. From a competitive binding assay 
and 1H15N chemical shift perturbation studies, a direct binding interaction 
between MIF and the N-terminal 27 residues of CXCR4 is shown. 
Titration studies using steady-state fluorescence spectroscopy resulted in 
a dissociation constant of 3.1 x 10-6 M. Notably, LmMIF/MIF-triggered 
monocyte chemotaxis activity is ablated by this N-terminal CXCR4 
peptide.  
 
The present study not only provides a crystallographic characterization of 
the prototypic MIF inhibitor 4-IPP for a potential treatment of MIF-
related autoimmune and inflammatory diseases, but also unfolds possible 
new pathways of parasitic MIF-orthologs to interfere with the host 
immune system. The study of the molecular mode of interaction of MIF 
and its binding partners will provide new opportunities to block these 
interactions specifically, and thus may aid in the design of new drugs 
targeting MIF-related diseases and immune evasive strategies of 
parasites. 
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